Entities

Version One Ventures is a Vancouver-based, early-stage venture capital firm founded by Boris Wertz in 2012. The firm backs mission-driven founders who are early in new areas, with a focus on AI, robotics, deep tech, decentralized systems, SaaS, and marketplaces.

Wing Venture Capital is an early-stage venture firm founded in 2013 and based in Palo Alto, California, focused on stealth, seed, and Series A financings in companies building the AI-first technology stack. The firm is a long-term company builder, partnering deeply with founders in B2B technology.

CRV, formerly Charles River Ventures, was founded in 1970 and focuses on leading seed and Series A technology rounds. Its USD 750 million CRV XX was announced in August 2025. The earlier USD 1.5 billion AUM narrative is historical; current AUM/check policy remains unverified.

Entrepreneur behind Blueprint and the Don't Die community, focused on longevity and health measurement. Founder of Kernel, developing non-invasive brain measurement technology, and OS Fund, which backs science-based companies. His work connects consumer health, neurotechnology and investment in scientific engineering. Appeared at the Network State Conference and on Balaji Srinivasan's Network State podcast. Distinct from Coinbase co-founder Brian Armstrong.

Signal profile (Amazon Alexa Fund) Amazon Alexa Fund

General Catalyst invests across company creation, seed and growth equity. On 2024-10-24 it announced approximately USD 8 billion raised across strategies and accounts: approximately USD 4.5 billion core venture funds, USD 1.5 billion creation strategy and USD 2 billion separately managed accounts. These are distinct components, not a single fund or AUM. March 2026 USD 10 billion fundraising discussions were not a verified close in the completed research.

Northwell Health is a nonprofit New York-based health system providing hospital, ambulatory and community care, medical education and biomedical research. Its Feinstein Institutes include bioelectronic medicine and translational neuroscience, and its strategic corporate venture and innovation programme supports healthcare technology, company creation, commercial joint ventures and external investments. Northwell Holdings is the current published corporate venture/innovation arm; Northwell Ventures is a historical programme name verified in earlier primary investment sources. The existing InvestmentFirm database classification is preserved for compatibility; Northwell itself is a health institution, not an independent private VC partnership. Investor1601 represents the verified institution and its source-qualified venture programme without asserting a separate legal fund or SPV. John D’Angelo became president and CEO October1,2025; former CEO MichaelJ.Dowling remains CEO emeritus and adviser. Current published leadership includes MargaretCrotty board chair, KevinBeiner COO, JillKalman chief medical officer, MicheleCusack CFO, MaxineCarrington chief people officer, RichardMulry Holdings president/CEO and KateO’Donnell Holdings managing director/legal executive. The sourced roster covers thirty publicly named system executives, venture leaders, subsidiary operators, research affiliates and qualified board/emeritus advisers; it is not a claim to enumerate all system employees. Authentic public portraits are retained where available. The central northwell.edu directory was blocked during this audit, so current own2026 event rosters, subsidiary biographies, official appointments and professional-organization publications establish the roles with explicit dates and qualifications. Research and investment relevance includes bioelectronic medicine, neuromodulation, assisted communication/BCI, AI clinical automation and contactless patient monitoring. Existing investment records are preserved; aggregate financing, operating budgets, joint-venture commitments and internal portfolio values are not treated as LP fund closings or investor ticket amounts.

Berlin pre-seed and seed firm investing in health-tech and industrial-tech companies across Europe and the US. Typical initial checks €500k–€1.5m as co-lead or follower. Team listed on https://paceventures.com/about-us (accessed 2026-09-10): Marius Swart, General Partner; Luka Nićin, Associate; Gabriel Méhaignerie, Associate.

Plural Platform is a founder-led early-stage venture capital firm based in London, backing ambitious European tech founders building transformational companies. Co-founded by Taavet Hinrikus (Wise), Sten Tamkivi, Ian Hogarth, and Khaled Helioui, its mission is to have GDP-level impact on Europe.

Venture firm founded in 2017, formerly branded Section32, investing in technology and healthcare. The S32 exact record and separately existing GoldiSection32 record remain distinct pending deliberate identity/duplicate review.

Bain Capital is a global investment platform founded in 1984, with distinct Ventures, Life Sciences, Private Equity and other businesses. Individual strategy funds and check/stage policies are not parent-wide VC capacity. Merge Labs primary source names Bain Capital without specific business; other verified participation is assigned to the explicitly named affiliate.

Pre-seed and seed venture firm in San Francisco that backs scientists and engineers building companies to solve large global problems, including climate, disease, connectivity, and food. Founded in 2015 by Ela Madej and Seth Bannon; backed by dozens of billion-dollar-company founders.

Founders Fund invests in transformational science and engineering businesses from seed through growth, with dedicated growth vehicles. Historical Signal seed USD 500000–5000000 range and fifth-fund narrative do not establish current firm-wide bounds or latest capital scale. Individual checks and current AUM remain unverified.

Human Capital is a multi-stage venture firm that also helps founders assemble teams. The brand represents multiple separately existing entities. Current firm-wide check bounds, AUM and final fund closes remain unverified; HCM VI regulatory amount sold is distinct from a final close or target.

Global venture investor founded in 2000, investing from seed through growth and later stages. December 2025 closing exceeded USD 9bn across multiple vehicles; named funds are recorded separately. Lightspeed Management Company, Lightspeed India Partners and Faction require separate adviser/fund attribution.

Signal profile (Prime Movers Lab) Prime Movers Lab cb Founded: 2018

Sequoia Capital is a venture capital firm founded in 1972 by Don Valentine. Its present US and Europe business partners with technology founders from seed through growth and public-market expansion, with current portfolio interests including AI research and applications, developer infrastructure, cybersecurity, computing and healthcare technology. Its published team spans seed and early-stage investing, growth investing and operating specialists in talent, design, finance, technology, data and communications. Its US/Europe Sequoia Capital Fund, announced in October2021, is an open-ended permanent-capital structure that holds public investments and allocates capital to closed-end venture subfunds; its NAV is not a new cash fundraise. Sequoia announced its sixth seed fund and nineteenth venture fund in October2025. Sequoia is distinct from independent former regional businesses HongShan and Peak XV Partners, as well as separate Sequoia Heritage and Global Equities entities. The retained SequoiaCapital database alias represents this same US/Europe firm; its older investment and protected imported records remain separate pending an audited consolidation.

Partner at Khosla Ventures

Venture firm founded in 2004 investing across seed, early and growth stages. Its portfolio includes fusion, space hardware, batteries and direct neurotechnology. Historical Signal language describing USD100000 to over USD20million investment sizes is not a verified current firm-wide check policy; dated targets and LP estimates are retained separately from fund closes.

Pablo de la Torre is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Director of International and Multinational Business at Santander España. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles. The historical2022COFIDES report supplies the caption-bound portrait and fuller legal name; current published board affiliation comes from the separate2025roster.

Luis Antonio Rico is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Adviser in the State Secretary for Industry’s cabinet. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles.

Mercedes Storch is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Responsible for Fond-ICO Next Tech and International Relations at Axis. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles. The historical2022COFIDES report supplies the caption-bound portrait and fuller legal name; current published board affiliation comes from the separate2025roster.

David Noguera is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Assistant General Manager at Banco Sabadell. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles.

Inés Gloria Pérez-Durantez is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Deputy Director for International Services Trade and Digital Trade in Spain’s commerce administration. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles.

Marta Mulas is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Director of Financial Cooperation at AECID. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles.

Asier González is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Head of Corporate and Institutional Business at Santander España. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles.

María Ángeles Laso is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: International and Cross-Border Solutions for BBVA enterprise clients. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles.

Rocío Fernández is an independent COFIDES board member in its latest published2025roster. CIRSA’s current corporate-governance biography independently confirms her COFIDES audit/risk and sustainability responsibilities and describes more than30years at PwC in capital-markets and accounting advisory leadership. She studied economics and business at Universidad Complutense and corporate governance at IC-A. CIRSA identifies Avanza Previsión service as2021–2026, so the older COFIDES directory’s Avanza affiliation is retained as dated context rather than assumed current.

Javier Estévez is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Director of Business Solutions and Transformation at BBVA. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles. COFIDES’s official2022governance report identifies the same BBVA director with the fuller name Javier Estévez Zurita, distinct from the existing Mundi Ventures analyst JavierEstévez; no homonym alias is merged. The historical2022COFIDES report supplies the caption-bound portrait and fuller legal name; current published board affiliation comes from the separate2025roster.

Silvia Díez is named in COFIDES’s latest published board roster, explicitly dated October28,2025. That primary directory identifies the following professional affiliation: Director of State Funds at Instituto de Crédito Oficial. The listing establishes a board capacity rather than a COFIDES operating-investment position, exact fresh appointment date or personal financial subscription. Other affiliations are contextual and are not added as unverified employer roles. The historical2022COFIDES report supplies the caption-bound portrait and fuller legal name; current published board affiliation comes from the separate2025roster.

Cristina Mena appears in COFIDES’s July2026 business-development unit. ICEX’s own2025 biography describes her deputy business-development role, earlier teaching and training in financial derivatives at Instituto BME, and joining COFIDES in2006. She studied business administration at Alcalá and economics at UNED; her responsibilities include origination, transaction assessment and structuring equity/debt financing proposals.

José Carlos Villena joined COFIDES in2007 and has worked in monitoring, investment and development-finance functions. Its July2026 CV names him development-finance director and describes a2012–2013 secondment to World Bank MIGA. Earlier he worked at Mercer and Krämmer Marktforschung. He holds law, business and actuarial/financial qualifications from CarlosIII and postgraduate international-business and development training.

Olga Verdugo is named in COFIDES’s July2026 organisation chart as heading the cabinet and institutional-relations unit. The official ICEX Spain–UK2025 business-conference agenda also identifies her responsibility for cabinet, institutional relations and strategic projects. These primary sources establish the institutional role; a fuller public career biography and individually captioned portrait remain unverified.

Raúl Sánchez directs impact investments and is responsible for COFIDES-managed FIS. His July2026 biography describes more than25years across innovation, entrepreneurship, partnerships and investment, with earlier private/public and multilateral experience including Santander, Opinno, IDB and the UN. He holds a doctorate in international economics and development and a law degree from Universidad Complutense; personal cash allocations are not inferred from entrepreneurship experience.

José Luis Ocasar joined COFIDES in2008 and has held project-monitoring, investments and FONREC-management responsibilities; its July2026 CV names him director of the equity area. Earlier he worked in strategic projects, planning and management control at Orange España. He studied economics and business at Zaragoza and completed IESE and financial-analysis training.

Rafael Matos has led COFIDES impact and sustainability since2022. His earlier public-service work includes international-finance and ministerial advisory functions and economic/commercial representation in Malaysia and Brunei. His July2026 biography describes previous governance experience at CDTI, Red.es and international-financing bodies. He studied business administration at CUNEF and joined Spain’s commercial-technician and economist corps in2009.

Raúl Moreno has worked at COFIDES for more than a decade, previously in cabinet, institutional-relations and communications roles, and has directed corporate social responsibility since2025. His earlier Spanish public-service career included commercial representation in Honduras and secondment to the European Commission. He studied law at Sevilla and completed further international-development and management training.

Mónica de Linos joined COFIDES in2023 to lead audit and internal control. Her prior experience includes Arthur Andersen, internal audit at WestLB, ICO and Enusa, leadership of Fundación ICO and Fundación CNSE, and director-general duties at Axis. She trained in economics and business and is a registered statutory auditor. These earlier roles remain career context, not newly asserted current employment.

Carolina Fernández-Puebla was COFIDES deputy risk director from2011to2020, later directing finance and risk and currently finance. Her earlier work included financial and risk consulting at AFI and control responsibilities at Gespastor. She studied economics and business at Universidad Autónoma de Madrid and earned an AFI banking-and-finance master’s.

Yolanda Gómez de Segura has worked at COFIDES since2010 and directs investment strategies in funds and vehicles supporting internationalisation and inward investment. Her earlier experience includes Deutsche Bank, Commerzbank and Acciona Energía in financial analysis, risk and international projects. Her July2026 CV describes business-administration studies and executive and ESG training.

Ana Victoria Fernández joined COFIDES in1997 and leads corporate legal advice, litigation and general services in its July2026 CV. The biography describes coordination of independent compliance, anti-money-laundering and criminal-liability prevention functions. She studied law at Universidad Complutense. The published board list separately names her deputy-secretary capacity; these legal duties do not imply personal investment checks.

Jesús Fernández joined COFIDES in2026 to lead processes, technology and data, including technology strategy, digital transformation, data governance and adoption of artificial intelligence. His July2026 biography describes more than20years in executive technology/data positions across banking, insurance and consulting. He trained as a telecommunications engineer and holds relevant professional certifications.

Ana Cebrián joined COFIDES in2002, working on origination, analysis and transaction structuring, and directs its debt area in the July2026 directory. Her earlier financial roles included Reale Seguros, Eli Lilly and Vensy. She studied economics and business at Comillas and completed a Rotterdam School of Management MBA.

Fernando Aceña has held COFIDES business and corporate-development responsibilities since2007 and is named its talent-area director in the July2026 CV. Previously he worked in investment and business cooperation at ICEX and advised the Centre for the Development of Enterprise. His education covers law, international business management and development cooperation.

Alfonso Santos is COFIDES secretary general from December2025 and is named Alfonso Santos Alcalá in its published board-secretary roster. His previous public legal work includes Acuamed and the Spanish State Attorney’s offices in Murcia, Madrid and the agriculture ministry. He studied law at Universidad CarlosIII. The July2026 CV and October2025 board list identify distinct secretary-general and board-secretary capacities, not an inferred investing role.

Miguel Ángel Ladero joined COFIDES in2001 and has worked in legal advisory and investments. Its July2026 biography places him over investments from corporate resources and FIEX/FONPYME and describes responsibility for FONREC, FOCO and FIS. He studied law at Salamanca and completed an IESE EMBA. Reported portfolio-operation totals are professional experience metrics, not personal checks or new manager fundraising.

Miguel Tiana has been COFIDES director general since2022. Previously he worked at Banco de España, consulted for the World Bank, and spent a decade at Spain’s Treasury in external-debt and international-finance responsibilities. His published biography describes participation in public financing-instrument governance, economics studies at Universidad CarlosIII and an economic-policy management master’s at Columbia.

Ángela Pérez has led COFIDES as president and chief executive since July8,2024. Her finance career includes Barclays investment banking, a previous decade at COFIDES directing investments, and financial structuring and asset management at Elecnor. She studied economics and business at Universidad Complutense and completed IESE’s PADE programme. Her published COFIDES office is distinct from personal investment activity.

COFIDES is Spain’s public-private development-finance institution and statutory manager of several state investment instruments. Its exact commercial-company name is Compañía Española de Financiación del Desarrollo, COFIDES,S.A.,S.M.E., NIF A78990603, headquartered in Madrid. The published ownership split is53%Spanishstate and47%Santander,BBVA,Sabadell andCAF; these shareholders’ staff and treasury are not merged into its own institution. It finances internationalisation and sustainable-development projects and manages FIEX, FONPYME, FONREC, FOCO and FIS. FOCO is the separate Fondo de Coinversión,F.C.P.J., a public fund without legal personality with accounting segregated from COFIDES corporate resources; COFIDES is its statutory manager, not an interchangeable corporate-balance-sheet subscriber. Anaconda Biomed’s September23,2026 financing explicitly names FOCO managed by COFIDES. The institution’s current leadership CVs and July2026organisation chart publish executives across investment, equity, debt, funds, impact, development finance, technology/data, talent, legal and governance functions. JesúsFernández’s published remit includes digital transformation and artificial-intelligence adoption. The board list remains expressly dated October28,2025 and is represented as the latest published roster, rather than assuming every shareholder representative is a current operating investor. Public€2BFOCO,€400MFIS and€1BFONREC resources are programme budget allocations and deployment capacities, not external LP fundraising closes or individual investee checks. FEDES is managed by AECID with COFIDES support; the global Green Climate Fund and EUblending programmes are not copied as COFIDES-owned funds. Investee rounds are kept separate from fund budgets, approvals, facilities and corporate resources.

Almi Invest GreenTech AB is Almi Invest’s nationwide Swedish venture investment subsidiary for climate and environmental technology. It invests alongside private investors in early-stage companies developing proprietary hardware or software with measurable climate or nature benefits, including lower emissions, more efficient resource use, ecosystem restoration and biodiversity protection. Its investment themes include energy storage and grids, circular materials, transport and mobility, industrial production and buildings, and agriculture and food systems. The team supports portfolio companies through board work, strategy and introductions to co-investors. It manages the original GreenTech programme and the second Climate Fund launched in 2024; these public investment programmes complement private venture capital.

InnoEnergy is a European clean technology investment and industrial development platform. It backs early-stage companies and helps research-based technologies reach industrial scale through capital, commercial support, corporate partnerships and new-company building. Its work spans energy storage and batteries, renewable generation, hydrogen, industrial decarbonisation, smart grids, energy efficiency and circular-economy technologies. Alongside investments, it coordinates clean technology value chains and provides workforce skills programmes and graduate education. Established in2010 with support from the European Institute of Innovation and Technology, it operates through the Dutch legal entity KIC InnoEnergy SE and regional affiliates. The platform uses the InnoEnergy brand following a March2025 rebrand from EIT InnoEnergy.

Finance and corporate investment professional with banking and risk-management experience.

Finance executive with prior senior financial roles at Reed Elsevier and Cisco, and venture-finance experience. Joined InnoEnergy as CFO in2011.

Energy industry leader with experience in electricity infrastructure, corporate strategy and industrial energy purchasing.

Industrial mobility and clean technology executive with experience in renewable energy, electrification and corporate leadership.

Electricity industry executive previously chief executive of Elia, with experience in grid operations and European power markets.

Co-founder of InnoEnergy and an innovation management researcher and ESADE professor with a background in entrepreneurship and management consulting.

Education and technology entrepreneurship specialist with prior software, telecoms, venture capital and university incubation experience.

Energy policy and research executive previously deputy administrator general at France’s atomic and alternative energies commission.

Energy business executive with experience at DNV GL, Essent and oilfield services companies, working on energy advisory and company building.

Energy, environment and sustainability researcher with leadership experience at Karlsruhe Institute of Technology.

Nuclear engineering academic at Universitat Politècnica de Catalunya with research experience in energy systems.

Energy executive with earlier electricity-system operations leadership at Svenska Kraftnät and utility experience at Ellevio.

Climate and environmental policy specialist who previously served as Poland’s environment minister and worked in international climate negotiations.

Renewable energy and technology investor previously involved in wind-turbine engineering and technology commercialization.

Industrial energy and policy executive previously an innovation leader at Boryszew and Poland’s minister of treasury.

Engineering academic and university leader working on electrical energy systems and international research cooperation.

Corporate finance and governance executive with international Siemens leadership and supervisory-board experience.

BioScience Managers is an international healthcare investment manager founded by Jeremy Curnock Cook in2003. Its Australian legal entity is BioScience Managers Pty Ltd (ACN124669192, ABN60124669192), a Corporate Authorised Representative of Phillip Asset Management Limited; its own history says it joined the PhillipCapital group inMay2004. The separate UK affiliate is BioScience Managers UK Ltd (company10921802, FRN823533), an appointed representative of Sturgeon Ventures LLP. These distinct contracting entities are not duplicate institutional buyers. The firm finances private and public healthcare companies with an emphasis on genomic medicine, paediatrics and digital technologies. Source-proven neuroscience/deeptech investments include Global Kinetics/PKG wearable Parkinson’s measurement, Saluda Medical closed-loop neuromodulation and Rex Bionics robotic rehabilitation. Its current directory identifies17 professionals across investment, operations, board and industry advisory work; advisor and board roles are kept distinct. David Atkins’ October2022 Managing Partner appointment is historical, since he is absent from the current directory. Four historical funds have actual raised amounts supported by the manager’s own history and fund page; VenturesII launched in2023 remains open with no verified closing amount/date. The Türkiye BioScience Managers fund is legally managed by Maxis, with BioScience Managers a collaborating healthcare investor; no separate duplicate subscriber check or unsupported USD100M close is assigned here. The government’s Global Kinetics cumulative AUD39.91M translation-fund investment figure is not a new financing round or individual2021 ticket. Exact LP closing days and legal vehicle mapping beyond published names remain unverified; corporate group AUM and commitments are excluded from closed fund cash. Public biographies sometimes retain old external-company roles, which are source-qualified as career history rather than current outside appointments.

BioScience Managers industry adviser and dual-qualified clinician and mechanical engineer. His career includes diagnostics leadership at Oncimmune, health technology at McLaren Applied Technologies, clinical military training and academic innovation. Holds Imperial medical and engineering qualifications. Older Oncimmune CEO and outside-board labels are qualified as biography history rather than current executive appointments.

Finance leader responsible for finance, IT, secretarial work and governance at BioScience Managers. His biography dates CFO service to2004 and also identifies a manager directorship. Earlier work covered utilities, telecommunications and international accounting firms. Holds a University of West of England degree and UK/Australian chartered-accountant qualifications.

Joined BioScience Managers in2012 and works on life-sciences investment sourcing, negotiations and portfolio management. Previously researched intracellular trafficking as a Columbia University postdoctoral fellow. Holds a molecular biology and biochemistry PhD from La Trobe and Melbourne Business School MBA.

Finance and operations executive with healthcare investment, research-funding, strategy and governance experience. Earlier roles included Coopers & Lybrand Deloitte, Rothschild Asset Management and Telethon Kids Institute. Holds a commerce degree and is a Fellow of Chartered Accountants.

Healthcare investment adviser and BioScience Managers independent director and industry adviser. Founded Aisling Capital and worked on pharmaceutical, biotechnology and medical-product financing and advisory transactions. Holds a Harvard MBA and University of Delaware accounting degree. External board titles in the older biography are not asserted current.

Healthcare investor and physician with company formation, acquisition and public-listing experience in Australia and the US. His postgraduate clinical work involved anaesthetics and intensive care. Holds University of Melbourne medical qualifications and an IMD MBA; his manager biography identifies Saluda Medical board work.

Physician and biotechnology investor whose earlier investment work included Dillon Read, Ticonderoga Capital and Asset Management Company. Co-founded Helix Ventures in2009 and returned to Perth medical practice in2013 while continuing investment work. Holds University of Western Australia medical and Stanford MBA qualifications.

Neuroscientist and BioScience Managers industry adviser specialising in interactions between immune and nervous systems and inflammation in neurodegeneration. Southampton identifies him as Emeritus Professor and describes consultancy to the UK Dementia Research Institute director. Oxford-trained researcher; older manager-page funding-panel titles and its inconsistent training-year range are not carried forward as current facts.

Also published as Işıl Güney. Molecular biologist responsible for BioScience Managers’ Türkiye fundraising, portfolio and international collaborations. Co-founded Ulysses Advisory Group and previously worked at Bio Istanbul, Dana-Farber, Harvard Medical School and the Broad Institute. Holds a Brown University PhD in molecular biology, cell biology and biochemistry.

Founder of BioScience Managers, launched in2003 following leadership of Rothschild Asset Management’s life-sciences investment team. His work covers healthcare commercialisation, international expansion and company boards. Holds a natural-sciences MA from Trinity College Dublin and previously worked at the Institute of Cancer Research.

Fund accountant who joined BioScience Managers inMay2020. Oversees fund financial reporting, analysis and regulatory compliance. Earlier accounting work included Phillip Capital, Challenger Financial Services and Summatix. Holds a La Trobe economics/accounting degree.

Michael (Mike) Perry is a healthcare executive and BioScience Managers Venture Partner with experience in regenerative medicines, biotechnology and medical devices. His biography describes senior pharmaceutical and biotech leadership. Holds Guelph physics, veterinary medicine and biomedical pharmacology qualifications plus Harvard advanced-management training; outside-company titles in the manager biography are not independently asserted current.

Published as Professor Phil Beales in BioScience Managers’ adviser roster. Clinical geneticist studying ciliopathies and Bardet-Biedl syndrome; co-founded Axovia Therapeutics with Victor Hernandez in2020. Axovia’s own biography describes discovery, diagnosis and specialised patient-care work and UCL/Kings College training. His manager affiliation is advisory, without any inferred personal investment.

Marketing and communications specialist working on brand presence, investment-campaign messaging and online strategy for BioScience Managers. Her experience includes startups, agencies, health technology and IT. Holds Central Queensland University business-management/marketing and management qualifications plus a communication degree.

Joined BioScience Managers in2017 after consulting at CRSI on growth, financing and international commercialisation for technology companies. Her partner work includes investment leadership, portfolio management, fundraising and international relationships. Holds a Nottingham Trent business degree.

NAVCAP AB is a Swedish investment company that backs Swedish industrial businesses and early-stage startups, helping new business ideas reach the market. Its publicly documented technology investments include Rivus Batteries, which develops metal-free organic electrolytes and flow batteries for large-scale energy storage, and a historical listed shareholding in Toleranzia, a biotechnology business developing immune-tolerance treatments for rare autoimmune diseases. NAVCAP joined Rivus as a new investor in its December 2023 EUR525,000 equity financing. Owner and Managing Director Lars Ulin also chairs Rivus’s board, connecting the investment company with its portfolio company’s governance. NAVCAP is a Swedish aktiebolag registered as 556826-3882.

David Lin advises Primavera. He previously led global fund investing and Asian direct investments at Ontario Teachers’ private-equity business, after working at CITIC Goldstone Investment. His education includes an undergraduate degree from Toronto and an MBA from Western University’s Ivey school. The current advisory roster supports the affiliation without establishing a statutory manager appointment or a personal portfolio check.

Edward Han joined Primavera in 2014 and invests in industrials, clean technology and AI. The firm credits him with developing its climate-investment business. He previously worked in Ardian’s Beijing office and earned undergraduate science and graduate finance degrees at Tsinghua University. His sector remit is distinct from any undisclosed fund or company allocation.

Elsie Wong is responsible for recruiting and developing Primavera’s people. Before joining the firm she was a director in Deutsche Bank’s equity-capital-markets team. She studied business administration at Boston University and international affairs at Columbia. The published talent remit is preserved without inventing an exact chief-human-resources title.

Fabian von Heimburg leads Primavera’s European investment activity. He previously established a business using AI for CRM automation and investment advice in consumer products and renewable-energy technology, and worked at Google and the United Nations. The firm describes German government digital-economy advisory experience and current international leadership-network affiliations. He earned an economic-history master’s degree at the London School of Economics.

Frank Wang manages Primavera’s operational functions, including technology, facilities, logistics and project support, and contributes to technology, manufacturing and business-services investments. He previously held management roles at Amdocs, Cisco and Novell. His education includes economics at Peking University and computer science at the University of Nevada. He is the manager’s published Wang Guangran, not an assumed match to another technology founder named Frank Wang.

Fred Hu founded Primavera Capital Group in 2010 and serves as its chairman and chief executive. He directs strategy, talent development and investor partnerships. His prior career includes leading Goldman Sachs in Greater China and working as an IMF economist. Current first-party board biographies identify his Yum China, UBS and Chubb governance affiliations. He studied engineering at Tsinghua and economics at Harvard. The SEC fund filing identifies him as Fred Zuliu Hu; fund governance does not establish a personal company check.

Gigi Ng is Primavera’s chief financial officer and chairs its corporate social-responsibility committee. Her previous experience includes investment banking at Goldman Sachs, Morgan Stanley and Schroders, and managing Goldman Sachs’ strategic-cooperation office with ICBC. She studied economics and art history at the University of Virginia. The firm also publishes her full name as Gigi Ng Sum Yi.

Haitao Zhai is a founding Primavera partner who leads financial-services investing and co-leads healthcare. His biography describes previous senior Goldman Sachs roles and earlier work at the People’s Bank of China. The manager also lists outside independent-board affiliations. He studied economics at Peking University, international affairs at Columbia and business administration at New York University.

Jeffrey Lau is a Primavera partner leading private credit and special situations. His earlier career involved private investments with sovereign funds, companies and family offices, as well as investment roles at Och-Ziff, Blackstone and Morgan Stanley. He was a Village Roadshow Entertainment investor and director during 2012–2017, a historical affiliation. He earned undergraduate and business graduate degrees at Harvard.

Jiaqi Zheng is a founding Primavera member leading or co-leading healthcare and technology, media and telecommunications investments. The manager lists board responsibilities at LBX Pharmacy Chain and Jenscare Biotechnology. He previously worked in China International Capital Corporation’s investment-banking department. He studied economics at Manchester and finance at Lancaster. These institutional roles do not imply personal checks.

Jimmy Guo joined Primavera in 2013 and works on industrial and technology investments. He previously worked in Bank of America Merrill Lynch’s Hong Kong investment-banking division. His education includes a Wharton MBA and a science master’s degree from the University of Manchester. The published joining year is qualified without inventing an exact appointment day.

Johnny Zou co-leads Primavera Venture Partners, a unit identified within the group’s own team directory. His investment focus includes AI, medical technology and equipment, cloud services, shared-economy businesses and cross-border opportunities. He studied history at Yale and economic history at the London School of Economics. The published unit affiliation is qualified without creating an unverified separate legal fund manager.

Jun Gao is responsible for Primavera’s brand, communications and media relationships. His earlier career includes a senior marketing role at a fintech company and editorial leadership at Sina, Hexun and Tencent. He studied accounting at the Central University of Finance and Economics and law at Peking University’s School of International Relations. These are published operational responsibilities rather than an inferred investment-partner title.

Kenneth Wong is a founding Primavera partner responsible for special-situations investing and a member of its investment committee. He co-chairs portfolio monitoring and management and previously led financial-services investments. His earlier banking roles were at Goldman Sachs and UBS. He studied law at Cambridge. This identity and career are distinct from the existing Pavilion/Seviora investment director named Kenneth Wong.

Lu Li joined Primavera in 2015 and invests in consumer, retail, financial and education businesses. She previously worked in Credit Suisse’s New York mergers-and-acquisitions group. Her education includes applied mathematics at Columbia and an MBA from Wharton. The current manager biography establishes this identity and remit; no unrelated namesake is merged.

Maggie Chen advises Primavera and founded Forecourt Partners, which advises families on wealth and succession planning. The firm also identifies an adjunct teaching affiliation at the University of Hong Kong. Her earlier investment career includes Junson Asset Management, SAFE Investment Company, AIG Capital and Morgan Stanley. She studied business at Michigan Technological University and earned a Yale MBA. This is a published advisory affiliation rather than an asserted full-time employee role.

Max Chen is a founding member of Primavera Capital Group, leading technology, media, telecommunications and education investing and co-chairing its culture and human-capital committee. The firm also identifies his Hong Kong Stock Exchange Listing Committee affiliation. His earlier investment-banking career was at Goldman Sachs in Hong Kong and New York. He studied applied mathematics at Harvard College and earned Harvard law and business graduate degrees.

Michael Woo leads Primavera’s Southeast Asian investments from Singapore. His earlier career includes co-leading Asia-Pacific financials at BofA Securities, investment banking at Goldman Sachs and structured credit at JPMorgan. He earned an undergraduate degree at Stanford. The published regional investment remit does not identify an independent fund allocation or legal employer subsidiary.

Ning Zhu is Primavera’s senior macro strategist and a finance professor at Shanghai Jiao Tong University’s Shanghai Advanced Institute of Finance. His published expertise concerns behavioural finance and the Chinese economy. Previous positions included Lehman Brothers and Nomura, and he has authored books on investment and financial markets. He earned an undergraduate degree at Peking University and a doctorate at Yale. Academic and manager affiliations remain separately qualified.

Philip Hu is a founding member and managing director of Primavera. He participates in its leadership, strategic-partnership, portfolio-management, ESG and operations committees. His previous career includes Hong Kong investment banking and a San Francisco hedge fund. He holds a science bachelor’s degree from Cornell. Committee and career affiliations are source-qualified rather than expanded into invented outside appointments.

Stephen Zhang is a founding Primavera member who leads or co-leads consumer, advanced-manufacturing and business-services investments. He co-chairs the culture and human-capital committee, and the firm lists a 4Paradigm board affiliation. His prior career was in Morgan Stanley’s special-situations and investment-banking businesses. He earned business-administration undergraduate and graduate degrees at Tsinghua.

Wanda Wang is a founding member of Primavera responsible for onshore investor relationships and government and regulatory communications. Her prior career includes operating and governance responsibilities at Broad Green Energy, Broad Group and Meishi Power. She studied at Hunan Normal, Peking and Columbia universities. Her committee and executive history does not establish a personal investment allocation.

Wei Wang joined Primavera in 2011 and invests in consumer, retail and healthcare businesses. He previously worked as an auditor for KPMG in China and Mongolia. He studied accounting at Peking University and is identified as a member of the Chinese Institute of Certified Public Accountants. The named current manager portrait and biography define this identity; unrelated same-name professionals remain separate.

William Wang is a founding Primavera partner who leads growth-capital investments and co-chairs portfolio monitoring and management. He previously served in Goldman Sachs’ principal-investment business and at China International Capital Corporation. He studied engineering management, computer science and management science at Shanghai Jiao Tong University. This biography is distinct from the existing ChipAgents founder and Scion Life Sciences fellow with the same English name.

Xu Chen oversees legal and compliance matters at Primavera. Her earlier legal experience includes China International Capital Corporation in Hong Kong and Fangda Partners in Hong Kong and Beijing. The firm identifies her admission to practise in New York and law degrees from Peking University and the University of California, Berkeley. No statutory directorship or personal investment authority is inferred from these responsibilities.

Harry Zhang (Harry Zhang) is published in Korea Investment Partners’ current Singapore Partners directory as Associate. Harry began his VC career at Singtel Innov8, where he worked on early-stage investments. He now invests in early- and growth-stage companies across Asia, primarily in proptech and consumer, while also exploring fintech and insurtech. He is particularly interested in markets where distribution and regulation can create lasting advantages, and places strong emphasis on the quality of the founding team. Published education: B.Eng., Chemical Engineering, National University of Singapore. The primary profile’s career/background list names Singtel Innov8; undated entries are not independently verified concurrent appointments. Published areas: Proptech, Fintech, Consumer. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Youlim Choi (최유림) is published in Korea Investment Partners’ current Singapore Partners directory as Assistant Manager. Youlim began her career at ATOZ after studying Accounting and Finance at the University of London. She worked on accounting and tax matters for clients across a range of industries, building practical experience in financial reporting and compliance. She later joined Korea Investment Partners to work more closely with the financial and operational needs of a single organization. At KIP Singapore, Youlim is responsible for accounting, fund administration, and office operations, with a focus on maintaining accurate and transparent financial and administrative processes. Published education: B.Sc., Accounting and Finance, University of London. The primary profile’s career/background list names ATOZ CONSULTING PTE. LTD.; undated entries are not independently verified concurrent appointments. Published areas: Accounting, Finance Management, Fund Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Tracxn co-founder and a named personal angel participant in Consuma’s October2025 seed financing.

Advait Nawathe’s self-published professional profile lists a Consuma affiliation and HEC Paris education. The accessible profile omits his exact role and affiliation dates; no current employment contract is asserted.

Akash Bhargava works on product and growth at Consuma after earlier work at Kirana Club. His own posts describe joining Consuma and building its product and research publication; the current SpacetimeDB event organizer names him VP Product & Growth at Consuma.

Consuma publishes Ankur D under Engineering. The company card gives a surname initial without an individual profile link; the initial is preserved rather than expanded.

Founder of Swatantra Wealth and a named personal angel participant in Consuma’s October2025 seed financing.

A named personal angel participant in Consuma’s October2025 seed financing. His ticket and investment vehicle are undisclosed; no employer or fund participation is inferred.

Fynd co-founder and a named personal angel participant in Consuma’s October2025 seed financing.

Mahitha Ramesh describes working on the Consuma brand in her own recent event account, republished by Akash Bhargava, and is named in Consuma’s current event recap. Her exact corporate job title and appointment dates are not established; an older indexed personal profile still carries a Cashfree affiliation.

Founder of Udhyam Learning Foundation and a named personal angel participant in Consuma’s October2025 seed financing.

Rishita Moolchandani’s self-published professional profile lists Consuma and education at Christ University. The accessible profile omits her exact role and affiliation dates. She is not merged with the separately published Rithika card.

Consuma publishes Rithika under Growth Marketing. The company card does not disclose a surname or individual profile link.

Consuma publishes Riya as Research Analyst. The company card does not disclose a surname or individual profile link.

Consuma publishes Sachin Krishna under Product Marketing. This company-directory attribution does not establish the dates or exclusivity of his employment.

Sachin Shankar Balasubramanyam works on Consuma engineering. His July2023 self-published announcement described moving from a16-month internship to full-time work at Consuma AI; an attached PESU Venture Labs profile identified him as lead developer working on its web-data, AI and NLP architecture. The current company directory publishes him as Sachin Shankar under Engineering.

Named personal angel participant in Consuma’s October2025 seed financing. Equirus’s announcement describes him at that date as Vice President at Titan Capital Winners Fund; his personal investment is not attributed to that fund.

Siddharth Tawker self-publishes a Consuma professional affiliation and describes work on consumer research following marketing experience. Consuma names him in its current MarTech/DigiPlus event recap. No exact job title or employment dates are disclosed in the accessible source.

Siddhartha Sharma leads sales at Consuma. His own announcement describes joining Consuma after Darwinbox and earlier enterprise-SaaS founding and go-to-market work; Consuma’s current event publication expressly calls him its Head of Sales.

Taher Dossaji’s self-published professional profile lists Consuma and PES University. The accessible profile omits his exact job title and affiliation dates.

Consuma publishes Vibhav under Growth & Strategy. The company card does not disclose a surname or individual profile link.

Yash Nikhil Mutnalkar is published in Consuma's Founder’s Office as Yash Mutnalkar. His same personal profile publishes the fuller name and Consuma product and fundraising updates.

Consuma develops AI software that turns publicly available consumer conversations and other digital signals into market-research reports for brands, marketers and consumer-insight teams. Its Rapid Research Platform accepts a free-text brief covering questions such as consumer sentiment, emerging trends, audience segmentation, product opportunities or competitors. Users specify geography, time period and other constraints, then either let the platform configure the research or refine sources and filters in Pro Mode. Consuma gathers material from sources including social media, public forums, product reviews, news, marketplaces and search trends, and uses a multi-agent AI analysis workflow to identify themes, sentiment and behavioral patterns. Reports combine findings, charts and recommendations and can be delivered in presentation or PDF formats. The platform supports campaign and product planning, competitive intelligence, trend tracking and social listening. Consuma was founded in2021 in Bengaluru and operates under the legal name Consuma Technologies Pvt Ltd.

Abhilash Madabhushi founded Consuma in2021 and leads its product, innovation and technology work. Consuma develops AI software for consumer and market research.

Jieun Kim (김지은) is published in Korea Investment Partners’ current U.S. Partners directory as Assistant Manager. Jieun(Jinny) is an Assistant Manager at KIP US, where she is responsible for accounting, monthly and annual financial closing, and external audit coordination. She also supports the day-to-day operations of the U.S. office and manages reporting and other requests from KIP headquarters. Through accurate financial management and reliable operational support, she helps maintain an effective operating environment for KIP US and enables the investment team to remain focused on its core investment activities. Published education: B.B.A., Business Administration, Duksung Women's University. The primary profile’s career/background list names Harley-Davidson of Korea; undated entries are not independently verified concurrent appointments. Published areas: Corporate Management, Accounting, Finance Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Minjoon Park (박민준) is published in Korea Investment Partners’ current U.S. Partners directory as Associate. Minjoon invests across AI, robotics, space, and energy, from early to growth stages. He focuses on companies with the potential to create new markets and build long-term value. He works closely with founders and supports portfolio companies across fundraising and growth. Rather than following short-term trends, Minjoon looks for businesses with lasting potential. Published education: B.A., Economics, Oberlin College. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: AI, Robotics, Energy. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Shane Ang (Shane Ang) is published in Korea Investment Partners’ current Singapore Partners directory as Director. Shane began his career launching a design business while studying Digital Animation at Nanyang Technological University, gaining firsthand experience in entrepreneurship. He later joined the VC team at a Singapore-based multi-family office, where he was drawn to the dynamic intersection of talent, technology, and capital markets — leading him to pursue venture capital full-time at Korea Investment Partners. He focuses on early and growth stage investments across Asia in the Proptech and Consumer sectors, and has recently been spending more time in Fintech and Insurtech — spaces where distribution dynamics and regulation tend to create durable moats. He looks for companies that can leverage these structural advantages into lasting competitive positions. Published education: B.F.A., Nanyang Technological University. The primary profile’s career/background list names Golden Equator Ventures; undated entries are not independently verified concurrent appointments. Published areas: Fintech, Insurtech, Consumer. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Synclare Kim (김종현) is published in Korea Investment Partners’ current Singapore Partners directory as Head of KIP Singapore. Synclare leads KIP Singapore, with a focus on fintech investments. He previously worked in financial industry research at Samsung Economic Research Institute and Woori Finance Research Institute, and built his investment experience at Mirae Asset Venture Investment and KTB Network. He is particularly interested in technologies that improve access to financial services and address inefficiencies in existing financial systems. He looks for founders who can turn those technologies into products and businesses that work in the real market. Published education: Ph.D., Management Information Systems, Graduate School of Business, Sungkyunkwan University. The primary profile’s career/background list names KTB Network, Mirae Asset Venture Investment, Samsung Economic Research Institute, Woori Finance Research Institute; undated entries are not independently verified concurrent appointments. Published areas: IT Convergence, Fintech, Insurtech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

David Suh (서정훈) is published in Korea Investment Partners’ current U.S. Partners directory as Head of KIP US. David began his career as a trader at Morgan Stanley and RBS in New York and Hong Kong. He later founded an e-commerce startup in Singapore and led strategic planning for Samsung’s mobile business in Southeast Asia, building experience across both finance and operating businesses. He then spent more than a decade at Samsung Ventures America, leading investments across semiconductors and deep tech and helping build the organization into one of Silicon Valley’s most active deep-tech investment platforms. In 2026, David joined Korea Investment Partners as Head of KIP US, where he leads the firm’s U.S. expansion and strengthens its global investment capabilities. He focuses on areas with strong structural growth, including AI data centers and infrastructure, energy, vertical AI, and bio and healthcare. Published education: B.S., Economics, Wharton School, University of Pennsylvania. The primary profile’s career/background list names Morgan Stanley, RBS, Samsung Ventures America; undated entries are not independently verified concurrent appointments. Published areas: Semiconductor, AI, Deeptech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jin Yoon (윤서진) is published in Korea Investment Partners’ current U.S. Partners directory as Principal. Jin began his venture investing career at Plug and Play, where he worked closely with early-stage founders and supported investment activities. The experience shaped his interest in companies that address problems at a systems level and change how organizations and industries operate. He invests across AI, robotics, space and defense, and deep tech in the U.S. and Europe. He focuses on strong founding teams tackling important problems with technologies that have the potential to reshape industries. Published education: B.S., Management Information Systems & Supply Chain Management, Kelley School of Business, Indiana University M.S., Technology Entrepreneurship, University of Notre Dame. The primary profile’s career/background list names Plug and Play Investment Team; undated entries are not independently verified concurrent appointments. Published areas: DeepTech, Software, Mobile. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Joon Hyun (현석준) is published in Korea Investment Partners’ current U.S. Partners directory as Director. Joon began his career at Korea Investment Partners and has since invested in more than 40 companies across North America, Europe, and Asia. He believes in building relationships and making investments on principles he can stand behind, even when the outcome does not go as planned. Rather than looking at companies in isolation, he considers the broader direction of technology and industry and looks for teams that can help shape what comes next. He invests across AI, robotics, bio, and platforms, with a focus on technologies that can change how industries are built and operate. Published education: B.A., Economics, University of California, Berkeley. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: ICT, Bio, Healthcare. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Keila Kim (김연주) is published in Korea Investment Partners’ current U.S. Partners directory as S. Associate. Keila focuses on life sciences investments across biopharma, next-generation biotechnology platforms, and the convergence of biology and technology. She joined Korea Investment Partners in 2022 as a biotech analyst and has since worked on both direct and GP investments in Silicon Valley. Her familiarity with both the U.S. and Korean biotech ecosystems also supports her work across cross-border investment opportunities. She evaluates companies based on scientific differentiation, commercialization potential, and scalability. She is particularly interested in companies where strong science can translate into viable products, therapies, and healthcare solutions with the potential to reach meaningful scale. Published education: B.S., Biology, University of California, Berkeley. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Mijin Han (한미진) is published in Korea Investment Partners’ current U.S. Partners directory as Principal. Mijin began her career at PwC in transaction advisory and audit before moving into investing at NT Capital. She later joined McKinsey & Company, where she advised private equity clients on technology-related projects. Her experience across advisory and investing eventually led her to focus on venture capital. She invests primarily in healthcare and fintech. She is interested in companies tackling problems that remain poorly solved and looks closely at whether the market is large enough, the business can scale, and the team can execute. Published education: B.A., English Literature, Rice University M.B.A.,Booth School of Business, University of Chicago. The primary profile’s career/background list names McKinsey, NT Capital, PwC; undated entries are not independently verified concurrent appointments. Published areas: Healthcare, Fintech, Insurtech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Cutey Lv (Cutey Lv) is published in Korea Investment Partners’ current China Partners directory as Assistant Manager. Cutey is an Assistant Manager on the KIP Shanghai, handling HR and financial management. She joined KIP right after graduating in 2015, having earned her bachelor's degree in Tourism Management from Kangwon National University, and previously worked at Postal Savings Bank of China Co., Ltd. She currently manages core financial functions including fund settlements, expense reimbursement review, bill and seal management, bank account reconciliation, payroll and benefits disbursement, procurement for the Beijing and Shanghai offices, and fund risk management. She is now looking to expand beyond execution into fund management, guided by core principles of cash flow visibility, pre-investment expenditure compliance, and audit readiness. Published education: B.B.A., Tourism Management, Kangwon National University. The primary profile’s career/background list names Postal Savings Bank of China; undated entries are not independently verified concurrent appointments. Published areas: HR, Finance Management, Accounting. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Bruce Hong (홍경진) is published in Korea Investment Partners’ current China Partners directory as Associate Director. Bruce, Associate Director, is based at KIP's Beijing office, managing the firm's China-focused funds and leading new fund formation. He previously spent five years at KVIC's China office running the Korea Fund of Funds' China allocation program, and building investment and industry networks in China. He brings deep insight into China's capital markets and industrial ecosystem to KIP. He views venture investment as backing future value and innovation for social progress and investor returns, and sees the firm as a platform for shared success. Published education: B.A., Political Science and Law, Fudan University. The primary profile’s career/background list names Lotte Confectionery China Holdings, KVIC China office; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, LP Relations. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Cathy Jin (Cathy Jin) is published in Korea Investment Partners’ current China Partners directory as Director. Cathy is Director of KIP China, having joined right after university in 2009 and built her entire career there. Her role spans fundraising support, portfolio investment & exit support, fund distributions and liquidation, investor relations, AMAC compliance, finance/tax, and AML — including managing multiple QFLP and JV funds through their full lifecycle from formation to liquidation. With over 17 years of experience in cross-border VC fund operations, she brings deep expertise in complex fund structuring and multi-jurisdiction execution, while also exploring AI to improve workflow efficiency. Cathy is a CPA, holds a B.A. from Central University of Finance and Economics, and is fluent in Chinese, Korean, and English. Published education: B.A., Public Administration, Central University of Finance and Economics. The primary profile’s career/background list names KIP China; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Fundraising. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Charlie Wang (Charlie Wang) is published in Korea Investment Partners’ current China Partners directory as Director. Charlie is the Director of the Compliance Team at KIP, where he oversees legal affairs related to KIP China's operations, ensuring regulatory compliance and risk mitigation for the firm's activities in the region. Prior to joining KIP, Charlie was a partner at Grandall law firm. Before that, he practiced as an associate in several prominent law firms, including King & Wood, Huatang, and Gray & Perkins (Beijing Office). He holds both an LL.B. and LL.M. from Renmin University of China. With deep expertise in legal due diligence and compliance frameworks, Charlie plays a critical role in safeguarding KIP's investments and supporting the firm's strategic objectives in the dynamic market of the Greater China region. Published education: LL.M. / LL.B., Renmin University of China. The primary profile’s career/background list names Grandall law firm, King & Wood Mallesons, Huatang law firm, Gray & Perkins Beijing Office; undated entries are not independently verified concurrent appointments. Published areas: Legal, CDD, Risk Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

David Hong (David Hong) is published in Korea Investment Partners’ current China Partners directory as Manager. David majored in Law at Beijing University of Chinese Medicine and built a solid foundation in corporate compliance, legal documentation, and administrative operations at Samsung Electronics China. He holds multiple professional qualifications, including the PRC Bar, CTA, CMA, CIA, and PMP certifications. He currently leads day-to-day financial operations for FMC and its funds at Korea Investment Partners' Shanghai office, overseeing accounting, cash flow management, financial reporting, and regulatory compliance. He also carries out post-investment activities such as portfolio monitoring, performance tracking, and operational support for portfolio companies, integrating his legal, tax, financial, and project management expertise into fund operations to support sustainable value creation. Published education: B.L., Law, Beijing University of Chinese Medicine. The primary profile’s career/background list names Samsung Electronic (China), Perfect CPA; undated entries are not independently verified concurrent appointments. Published areas: Accounting, Finance Management, Fund Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Reco Yu (Reco Yu) is published in Korea Investment Partners’ current China Partners directory as Director. Reco is Director of the Risk Management at KIP Shanghai. She is instrumental in shaping the firm's investment success by leading comprehensive financial due diligence and managing the ongoing accounting activities of portfolio companies. Prior to joining KIP China, she worked at Intertek and KPMG. She received her BBM from Shanghai University of Finance and Economics. Published education: B.B.M., Business Management, Shanghai University of Finance and Economics. The primary profile’s career/background list names Intertek, KPMG; undated entries are not independently verified concurrent appointments. Published areas: Risk Management, Audit, FDD. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Grace Kim (김지수) is published in Korea Investment Partners’ current China Partners directory as Head of KIP Beijing. Grace, Head of KIP's Beijing Office, previously served as a full-time professor at Paichai University before joining the Korea Health Industry Development Institute (KHIDI). In 2012, she was posted as KHIDI's China branch chief, leading the Korean health industry's expansion into China. Through that experience, she recognized that corporate exchange alone couldn't drive real outcomes without capital, which deepened her appreciation for the role of VC — leading her to join KIP's China division in 2015. She focuses on early-stage investments across healthcare, bio, AI, and consumer sectors. In pharmaceuticals she favors a fast-follower strategy, while in other areas she prioritizes CEO drive, whether the technology solves a genuine market pain point, and the potential to secure data for AI and future industries. Published education: Ph.D., Acupuncture-Moxibustion Tuina, Beijing University of Traditional Chinese Medicine. The primary profile’s career/background list names Korean Embassy(China), KHIDI, Baejae University; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Leo Lin (Leo Lin) is published in Korea Investment Partners’ current China Partners directory as Director. Prior to joining Korea Investment Partners, Leo worked at SIG Asia Investment and Baidu, gaining experience across both technology and investing. With a background in physics, he focuses on understanding how emerging technologies scale into real-world industries and translating those insights into investment opportunities. He invests in AI, robotics, and consumer sectors, with a focus on real-world applicability and scalability of technology. In complex and fast-moving environments, he focuses on identifying core signals amid noise and backing companies with the potential for sustained, long-term growth. Published education: B.S., Physics, Peking University. The primary profile’s career/background list names CDH Funds, SIG Asia Investment, Baidu Strategy Office; undated entries are not independently verified concurrent appointments. Published areas: AI, Robotics, Semiconductor. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Michelle Zheng (Michelle Zheng) is published in Korea Investment Partners’ current China Partners directory as Associate Partner. Michelle is Associate Partner at KIP's Shanghai office. Prior to joining KIP, she worked at Fosun Pharma, Newmargin Capital, and Ipsos Group S.A., building experience across corporate strategy consulting, venture capital, and the biotech sector. She graduated from NUS (National University of Singapore) with an MBA and from Shanghai University with a Bachelor's degree in Business Management. She focuses on early-to-growth-stage tech and hard-tech investments (Series A–C). She believes technology must translate into validated applications and tangible customer value, favoring companies with strong R&D, clear commercial paths, and robust execution. Published education: B.B.M., Business Management, Shanghai University M.B.A., Concordia University. The primary profile’s career/background list names Fosun Pharma, New Margin, IPSOS; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Richard Cui (Richard Cui) is published in Korea Investment Partners’ current China Partners directory as Director. Prior to joining Korea Investment Partners, Richard worked at Mitsui Global Investment and Samsung (China) R&D, building experience across both capital markets and technology development. He entered the VC industry over 15 years ago, drawn to what he describes as the ongoing interplay between technology and humanity — a space where exceptional talent comes together to shape the future. He focuses on opportunities across AI/Computing, Robotics, Space, Energy, and cross-border investments. He takes a conviction-driven approach, investing without being constrained by stage or valuation when confident in a company’s ability to reach its next milestone. This approach has led to multiple successful exits through M&A and IPO. Published education: B.S. in Business & Computer Science, Tianjin University. The primary profile’s career/background list names Mitsui Global Investment, Samsung (China) R&D; undated entries are not independently verified concurrent appointments. Published areas: TMT, AI, DeepTech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Ziye Song (Ziye Song) is published in Korea Investment Partners’ current China Partners directory as VP. Ziye is a VP of Investment at Korea Investment Partners' Shanghai office. Prior to joining KIP, he worked at Salesforce in San Francisco, Tencent in Shenzhen, and Ceyuan Ventures in Beijing, gaining a combination of product experience in Silicon Valley, Chinese tech platform experience, and early-stage venture investing experience. He holds a bachelor's degree in Electrical Engineering and Computer Sciences (EECS) from UC Berkeley. He focuses on early- to growth-stage technology investments, primarily from Series A to Series C, where technical differentiation has begun to translate into product validation, customer adoption, or strategic supply-chain relevance. His technical training shapes his investment approach: he is particularly interested in companies where deep engineering capability, product-market timing, and operating excellence jointly determine long-term value creation, combined with clear commercialization paths and strong company-building execution across technology, go-to-market, and team development. Published education: B.S., Electrical Engineering and Computer Science, University of California, Berkeley. The primary profile’s career/background list names Salesforce, Tencent; undated entries are not independently verified concurrent appointments. Published areas: AI, Robotics, Consumer. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Heeyun Choi (최희윤) is published in Korea Investment Partners’ current Operations Partners directory as Assistant Manager. Heeyun is an Assistant Manager on the Global Strategy Team, where he supports offshore fund management and the global expansion of KIP’s portfolio companies. Drawing on his previous experience on the Fund Planning & Management Team, he brings a data-driven approach to fund management while helping connect KIP and its portfolio companies with opportunities in international markets. Before joining Korea Investment Partners, he worked as a manager at accelerator Kimgisa Lab, where he gained broad exposure to the venture ecosystem, with a focus on early-stage startups. Building on his experience across both fund management and the startup ecosystem, he now helps KIP and its portfolio companies identify new opportunities and expand their presence globally. Published education: B.S., Mathematics, University of Washington. The primary profile’s career/background list names Kimgisa Lab; undated entries are not independently verified concurrent appointments. Published areas: Global Expansion, Overseas Business, Fund Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hudson Ho (호경식) is published in Korea Investment Partners’ current China Partners directory as Head of KIP China (Shanghai). Hudson, Managing Partner, felt the limits of advising clients from the outside as a consultant and concluded it would be more meaningful to execute directly or share in the results himself. In 1999, he founded and ran an internet company, growing it to about 20 employees and raising venture capital, before selling it to a listed company in its second year — an experience that drew him into VC and led him to join KIP. In Korea, he invested in semiconductor and internet platform companies such as Neofidelity, WiSol, ICreditable, and AfreecaTV. After establishing KIP's China office, he expanded into consumer internet, high-tech, and biotech investments including DiDi, Henlius, Weimob, and Ambiq. He places the highest value on a founder's problem-solving ability, leading early-stage investments in industries with strong expected growth and selecting companies that can secure clear technological differentiation. Published education: B.B.A., Business Administration, Seoul National University. The primary profile’s career/background list names Accenture (Anderson Consulting); undated entries are not independently verified concurrent appointments. Published areas: TMT, Bio, Semiconductor. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jeonghyun Cha (차정현) is published in Korea Investment Partners’ current Operations Partners directory as Assistant Manager. Jeonghyun is an Assistant Manager on the Asset Management Team, where he is responsible for fund accounting, financial reporting, external audit coordination, and tax matters. His role focuses on maintaining the accuracy and timeliness of financial information across fund operations. Before joining Korea Investment Partners, he worked on the accounting team at KOSDAQ-listed cybersecurity company Igloo Corporation. His responsibilities included financial closing, external audits, tax filings, and corporate administration, providing him with broad experience in corporate accounting and financial management. Published education: B.B.A., Business Administration, Sejong University. The primary profile’s career/background list names Igloo Corporation; undated entries are not independently verified concurrent appointments. Published areas: Asset, Accounting, Audit. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Seungmin Lee (이승민) is published in Korea Investment Partners’ current Operations Partners directory as Associate. Seungmin Lee is an Associate on the Fund Planning & Management Team, where he supports funds throughout their lifecycle, from formation through liquidation. His responsibilities span fund formation and administration as well as coordination with LPs, startups, and other stakeholders involved in the investment process. Before joining Korea Investment Partners, he evaluated early-stage investment opportunities at Schmidt and later gained hands-on fund management experience at Mirae Asset Capital. His experience across both investment evaluation and fund administration has given him a broad perspective on managing investments beyond the initial decision. Published education: B.A., Economics, Hanyang University. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Investment Operations. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Beomjun Kim (김범준) is published in Korea Investment Partners’ current Operations Partners directory as Assistant Manager. Beomjun is an Assistant Manager on the Fund Planning & Management Team, where he works across the lifecycle of domestic venture funds and PEFs, from planning and formation through ongoing administration. He has supported multiple project fund formations as well as competitive and ad hoc institutional fundraising processes. Before joining Korea Investment Partners, he began his career as a fund management intern at DSC Investment and has continued to build his expertise in fund operations. He serves as a point of contact across fund management and investment teams as well as with other GPs and LPs. Published education: B.A., Economics, Chung-Ang University. The primary profile’s career/background list names DSC Investment; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Investment Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Eunji Park (박은지) is published in Korea Investment Partners’ current Operations Partners directory as Assistant Manager. Eunji is an Assistant Manager on the General Affairs Team, where she supports workplace operations across corporate assets, IT administration, employee benefits, and other internal services essential to the firm’s operations. Her background in customer service informs a service-oriented approach to internal operations and employee support. She also uses digital tools and data to streamline administrative processes and improve operational efficiency across the organization. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: General Affairs, Corporate Assets, Employee Benefits. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jeonghoon Lee (이정훈) is published in Korea Investment Partners’ current Operations Partners directory as Assistant Manager. Jeonghoon is an Assistant Manager on the Fund Planning & Management Team, where she is responsible for fund administration, regulatory reporting to the Financial Supervisory Service (FSS), and preparing proposals for institutional LPs. Her responsibilities also include LP communication across the fund lifecycle. Before joining Korea Investment Partners, she worked in fund management at Aju IB Investment. Her experience managing PEFs and venture funds, together with her work with anchor LPs, supports her current responsibilities across fund formation and ongoing administration. The primary profile’s career/background list names Aju IB Investment; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Investment Management. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Minjung Kim (김민정) is published in Korea Investment Partners’ current Operations Partners directory as Manager. Minjung is a Manager on the Fund Planning & Management Team, where she oversees the full lifecycle of domestic venture funds, from formation and ongoing administration through dissolution and liquidation. Her responsibilities include portfolio asset administration, transaction processing, equity-related administration, and the monitoring and reporting of distressed portfolio companies. Before joining Korea Investment Partners, she began her career at MG Non-Life Insurance, where she gained experience in financial operations. She later moved to Maple Investment Partners, formerly MG Investment, and developed hands-on experience across investment and fund management activities. The primary profile’s career/background list names MG Non-Life Insurance, Maple Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Investment Operations. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Soohyun Jeon (전수현) is published in Korea Investment Partners’ current Operations Partners directory as Manager. Soohyun is a Manager on the Fund Planning & Management Team, where he oversees internal systems, IT infrastructure, and information security. His responsibilities include ERP administration, systems availability, security controls, and the technology environment supporting the firm’s investment and corporate functions. He holds an M.S. in Physics from Dongguk University and worked at KGT Lab. Co., Ltd. before joining Korea Investment Partners. His analytical training informs a structured approach to systems and data management as well as the technical and operational issues that arise across the firm’s IT environment. Published education: M.S., Physics, Dongguk University. The primary profile’s career/background list names KGT Lab. Co., Ltd.; undated entries are not independently verified concurrent appointments. Published areas: Systems Management, IT Operations, Information Security. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Urim Sohn (손우림) is published in Korea Investment Partners’ current Operations Partners directory as Manager. Urim is a Manager on the Asset Management Team, where she oversees fund accounting, asset operations, and external audit coordination. Her work focuses on maintaining the financial accuracy and liquidity management required to support the firm’s investment activities. Before joining Korea Investment Partners, she worked at accelerator BigBang Angels, where she managed angel investment funds and planned and operated startup support initiatives, including incubation and TIPS programs. Her experience working directly with early-stage companies provides practical context for her current responsibilities in treasury and fund accounting. The primary profile’s career/background list names BigBang Angels; undated entries are not independently verified concurrent appointments. Published areas: Asset, Fund Accounting, External Audit. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Changho Kim (김창호) is published in Korea Investment Partners’ current Operations Partners directory as Head of Investment Support Department. Changho is Managing Director and Head of Investment Support at Korea Investment Partners, where he leads the Fund Planning & Management Team and the Global Strategy Team. He oversees the firm’s investment support functions across fund planning, formation, administration, fundraising, LP relations, and global initiatives. Before joining Korea Investment Partners, he worked on the Research Team at the Korea Venture Capital Association, where he developed a broad understanding of Korea’s venture capital industry and fund management practices. He brings that perspective to his current role overseeing fund operations, investor relations, and global activities across the Investment Support Office. Published education: B.A., Economics, Yonsei University. The primary profile’s career/background list names Korea Venture Capital Association; undated entries are not independently verified concurrent appointments. Published areas: Investment Operation, LP Relations, Fundraising. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Danny Kang (강무경) is published in Korea Investment Partners’ current Operations Partners directory as Head of Global Strategy Team. Danny leads the Global Strategy Team at Korea Investment Partners, overseeing domestic and international fundraising(LP relations), overseas fund management, strategic partnerships, and global initiatives. He is in charge of building and maintaining with new and existing LPs in Korea and global. He also supports the international expansion of portfolio companies and oversees the operations and capital formation activities of KIP’s overseas offices. Before joining Korea Investment Partners, he led open innovation at hardware accelerator N15, where he developed partnerships between startups and large corporations. That experience now informs his work connecting investors, corporates, founders, and international networks to create new investment and business opportunities. Published education: B.A., Sociology, University of Washington. The primary profile’s career/background list names N15; undated entries are not independently verified concurrent appointments. Published areas: Fundraising, Global Strategy, LP Relation. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Deukhee Kim (김득희) is published in Korea Investment Partners’ current Operations Partners directory as Head of Financial Management Team. Deukhee is General Manager and Head of Financial Management at Korea Investment Partners, where he oversees separate and consolidated financial reporting, corporate tax, external audits, and performance reporting to the holding company. He is responsible for the financial processes that support the firm’s investment and business operations. As a Korean Certified Public Accountant, Deukhee spent five years at Samil PwC in audit and financial advisory, working across a broad range of accounting, reporting, and tax matters. Since joining Korea Investment Partners in December 2017, he has continued to strengthen the firm’s financial reporting and management processes while managing the financial and tax risks associated with its growth. Published education: B.A., Economics, Chung-Ang University. The primary profile’s career/background list names Samil PwC / KICPA; undated entries are not independently verified concurrent appointments. Published areas: Accounting, Tax, External Audit. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hee Song (송희) is published in Korea Investment Partners’ current Operations Partners directory as Head of Fund Planning & Management Team. Hee is Executive Director and Head of Fund Planning & Management at Korea Investment Partners, where she oversees the full lifecycle of venture and private equity funds, from planning and formation through ongoing management and liquidation. She also leads from domestic institutional RFPs and proposal activities to liquidation process. With more than 18 years of experience at leading Korean venture capital firms, including LB Investment and KTB Network, she has built extensive experience across fund management, fund finance, accounting, tax, and LP relations. Drawing on her experience across a wide range of funds and operating environments, she leads domestic institutional investor communication and fund operations at KIP. The primary profile’s career/background list names LB Investment, KTB Network; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Fundraising. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hwang Kim (김황) is published in Korea Investment Partners’ current Operations Partners directory as Head of Management Support Department. Hwang is Managing Director and Head of Management Support at Korea Investment Partners, where he oversees the firm’s financial management, accounting, human resources, and corporate planning functions. He coordinates these areas across the organization to support the firm’s continued growth and investment activities. Before joining Korea Investment Partners, Hwang worked at the Venture Investment Information Center of the Korea Venture Capital Association, where he was responsible for regulatory affairs, industry statistics, and planning. This experience gave him a broad understanding of Korea’s venture capital industry, which he now applies across the firm’s management functions. Published education: B.B.A., Business Administration, University of Seoul. The primary profile’s career/background list names Korea Venture Capital Association; undated entries are not independently verified concurrent appointments. Published areas: Management Support, Financial Management, Corporate Planning. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Inho Hwang (황인호) is published in Korea Investment Partners’ current Operations Partners directory as Deputy General Manager. Inho is a Deputy General Manager on the Fund Planning & Management Team, where he oversees fund planning, fund administration, and portfolio asset management. A key part of his role is validating financial data and performance metrics and providing LPs with accurate, timely information throughout the fund lifecycle. Before joining Korea Investment Partners, Inho worked at LG Hausys in financial accounting, corporate planning, and management. His background in corporate finance and planning now informs his work across fund operations, data analysis, and investor reporting. Published education: B.A., Economics, Yonsei University. The primary profile’s career/background list names LG Hausys; undated entries are not independently verified concurrent appointments. Published areas: Fund Planning, Fund Management, Investment Operations. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jiyeon Lee (이지연) is published in Korea Investment Partners’ current Operations Partners directory as Manager. Jiyeon is a Manager on the Corporate Management Team, where she oversees human resources, employee benefits, and corporate operations. Her responsibilities include internal policies, administrative requirements, and HR programs across the firm. Before joining Korea Investment Partners in 2013, Jiyeon worked in fund custody operations at NongHyup Bank. Since joining KIP, she has held roles across investment administration and fund treasury management, building a broad understanding of the firm’s operational functions before moving into corporate management and HR. The primary profile’s career/background list names NongHyup Bank; undated entries are not independently verified concurrent appointments. Published areas: HR, Corporate Operations, Employee Benefits. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Okhwa Baek (백옥화) is published in Korea Investment Partners’ current Operations Partners directory as Head of Asset Management Team. Okhwa is Deputy General Manager and Head of Asset Management at Korea Investment Partners, where she oversees corporate treasury, fund and PEF accounting, financial reporting, and external audit coordination. With more than a decade of experience at KIP, she has worked across a broad range of fund administration and financial operations. Her experience spans complex financial and fund-related matters across different operating environments. As head of the team, Okhwa oversees treasury operations, accounting processes, and audit readiness, with particular emphasis on accuracy, consistency, and effective financial management. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Asset Management, Fund & PEF Accounting, External Audit. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Wooram Yoo (유우람) is published in Korea Investment Partners’ current Operations Partners directory as Head of Corporate Management Team. Wooram is Executive Director and Head of Corporate Management at Korea Investment Partners, where he oversees corporate planning, human resources, and general affairs. As a Korean Certified Public Accountant, he brings accounting and tax expertise to a broad range of management and operational matters across the firm. Before joining Korea Investment Partners, Wooram worked in the Financial Services Group at Samil PwC, providing audit and accounting advisory services to banks, securities firms, insurance companies, and venture capital firms. His experience across the financial sector now informs his approach to corporate planning and management as KIP continues to grow. Published education: B.B.A., Business Administration, Yonsei University. The primary profile’s career/background list names Samil PwC / KICPA; undated entries are not independently verified concurrent appointments. Published areas: Business Planning, Accounting, Tax. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Yongjae Kim (김용재) is published in Korea Investment Partners’ current Operations Partners directory as Head of Operation Division. Yongjae is Executive Managing Director and Head of Management Support at Korea Investment Partners, where he oversees fundraising, fund formation, LP relations, and the firm’s broader management support functions. He began his career at Korea Investment Partners in 1999 and has played a central role in developing the operating processes that have supported the firm’s growth. Since the early development of Korea’s venture capital industry, he has led a broad range of support functions at KIP. In particular, he has overseen fundraising for many years, contributing significantly to the expansion of the firm’s assets under management while building longstanding relationships with institutional investors and LPs. Published education: B.S., Marketing, University of Dubuque. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Management Support, LP Relations, Fundraising. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Giseok Park (박기석) is published in Korea Investment Partners’ current Private Equity Partners directory as Principal. Giseok is a Principal on PE Team 3 at Korea Investment Partners, where he invests across industrials, AI, and ICT. He looks across markets, technologies, and business models to identify differentiated companies with the potential to build lasting competitive advantages. Before joining Korea Investment Partners, he worked in the M&A practice at Samjong KPMG, advising on acquisitions and divestitures. He later joined the IPO Division at Mirae Asset Securities, where he sourced and invested in private companies and worked on IPO transactions, gaining experience across M&A, private investing, and capital markets. Published education: B.A., Economics, Sogang University. The primary profile’s career/background list names Samjung KPMG / KICPA, Mirae Asset Securities; undated entries are not independently verified concurrent appointments. Published areas: Industrials, AI, ICT. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hyoungsub Kim (김형섭) is published in Korea Investment Partners’ current Risk Management Partners directory as Manager. Hyoungsub is a Manager in the Risk Management Office at Korea Investment Partners, where he is responsible for risk monitoring, valuation, and financial due diligence across the firm’s funds and portfolio companies. His work includes reviewing the financial information and assumptions underlying investment and portfolio decisions. Before joining Korea Investment Partners, he worked in the Assurance practice at Samil PwC, conducting external audits across a range of companies. He also worked on valuations for financial reporting purposes and internal accounting advisory engagements, experience he now applies to portfolio risk assessment and valuation reviews at KIP. Published education: B.B.A., Business Administration, Yonsei University. The primary profile’s career/background list names Samil PwC / KICPA; undated entries are not independently verified concurrent appointments. Published areas: Risk Management, Internal Audit, Financial Due Diligence. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hyunsoo Go (고현수) is published in Korea Investment Partners’ current Risk Management Partners directory as Head of Risk Management Department. Hyunsoo is a General Manager and Head of Risk Management at Korea Investment Partners, where he oversees risk across investment decisions, funds, and portfolio companies. As a Korean Certified Public Accountant, he applies his financial and accounting expertise to assessing the assumptions, valuations, and financial information underlying KIP’s investments. Before joining Korea Investment Partners in 2016, he worked in M&A advisory and valuation at Deloitte Anjin, corporate credit analysis at Korea Investors Service, and audit and consulting at Samjong KPMG. His experience across valuation, credit analysis, and audit gives him multiple perspectives from which to assess both investment potential and the risks that accompany it. Published education: B.S. Earth and Environmental Systems Engineering, Seoul National University. The primary profile’s career/background list names Deloitte Anjin / KICPA, KPMG Samjong, Korea Investors Service; undated entries are not independently verified concurrent appointments. Published areas: Risk Management, Internal Audit, Financial Due Diligence. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

John MJ Kim (김민준) is published in Korea Investment Partners’ current Private Equity Partners directory as Principal. John is a Principal on PE Team 2 at Korea Investment Partners, where he focuses on growth investments across TMT, ESG, and deep tech. He evaluates emerging market opportunities created by technology while considering business models, competitive positioning, and financial fundamentals. Before joining Korea Investment Partners in 2020, John worked at Kiwoom Private Equity, where he executed growth investments across software, manufacturing, and other industries. His academic background spans food and resource economics and an interdisciplinary program in software technology and entrepreneurship at Korea University, and he is also a U.S. Certified Public Accountant. Published education: B.A., Food and Resource Economics & Software and Venture Engineering, Korea University. The primary profile’s career/background list names Kiwoom Private Equity / U.S. CPA; undated entries are not independently verified concurrent appointments. Published areas: TMT, ESG, DeepTech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

JunIk Jang (장준익) is published in Korea Investment Partners’ current Private Equity Partners directory as Principal. Junik is a Principal on PE Team 4 at Korea Investment Partners, where he focuses on investments across ICT, manufacturing, and materials, parts, and equipment. He evaluates business resilience, cash flow, transaction structure, and exit potential alongside a company’s growth prospects. He began building his investment experience through multiple private equity internships before joining DB Securities and later Truston Asset Management. His experience across the capital markets has shaped an investment approach that considers both structural growth opportunities and downside risk to invested capital. Published education: B.B.A., Business Administration, Hanyang University. The primary profile’s career/background list names DB Securities, Truston Asset Management; undated entries are not independently verified concurrent appointments. Published areas: ICT, Manufacturing, MPE. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Kilho Jeong (정길호) is published in Korea Investment Partners’ current Private Equity Partners directory as Principal. Kilho is a Principal on PE Team 1 at Korea Investment Partners, where he focuses on investments across ICT, manufacturing, and deep tech. He evaluates market structure, competitive positioning, and management execution across companies at different stages of growth. Before joining Korea Investment Partners, he worked at Kiwoom Private Equity and Shinhan Capital, executing buyout and growth capital investments and working closely with portfolio companies after investment. He joined KIP to take a more active role in long-term value creation beyond transaction execution. Published education: B.B.A., Global Business Administration, Sungkyunkwan University. The primary profile’s career/background list names Kiwoom Private Equity, Shinhan Capital; undated entries are not independently verified concurrent appointments. Published areas: ICT, Manufacturing, Deeptech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Sangheon Shin (신상헌) is published in Korea Investment Partners’ current Compliance Team directory as Compliance Officer / Head of Compliance Team. Sangheon is Compliance Officer, and Head of Compliance at Korea Investment Partners, where he oversees regulatory compliance, internal controls, legal advisory, and regulatory reporting. He advises the firm on legal and compliance matters across its corporate and investment activities. Before joining Korea Investment Partners, he worked in the legal departments of NAVER Corporation and Hyundai Motor Company, where his responsibilities spanned compliance, internal controls, legal advisory, and risk management. His experience across large corporate organizations now informs his work on contract review, investment-related legal matters, and regulatory requirements at KIP. Published education: B.B.A., Business Administration, Sogang University J.D., Sogang University School of Law. The primary profile’s career/background list names Naver / Attorney (Korea), Hyundai Motors; undated entries are not independently verified concurrent appointments. Published areas: Compliance, Legal Advisory, Regulatory Reporting. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Sanghwa Lee (이상화) is published in Korea Investment Partners’ current Legal Department directory as Head of Legal Department. Sanghwa is Head of Legal at Korea Investment Partners, where he oversees legal matters across the firm’s investment and corporate activities. He advises on investment agreements and other key contracts, assesses legal risks throughout the investment process, and provides counsel on matters requiring legal judgment. He studied economics at Seoul National University and earned his J.D. from Yonsei University School of Law. Before joining Korea Investment Partners, he worked at the Samsung Economic Research Institute and Dongseo Partners Law Firm. His background in both economics and law allows him to consider the commercial context of an investment alongside its legal implications. Published education: B.A., Economics, Seoul National University J.D., Yonsei University School of Law. The primary profile’s career/background list names Samsung Economic Research Institute / Attorney (Korea), Dongseo Partners Law Firm; undated entries are not independently verified concurrent appointments. Published areas: Legal, Risk Management, Due Diligence. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Seungbeen Paik (백승빈) is published in Korea Investment Partners’ current Risk Management Partners directory as General Manager. Seungbeen is a General Manager in the Risk Management Office at Korea Investment Partners, where he leads financial due diligence and supports post-investment monitoring across the firm’s portfolio. He provides an independent perspective on the financial assumptions and evidence underlying investment decisions. As a Korean Certified Public Accountant, he spent five years at EY Han Young in audit and financial advisory. Since joining Korea Investment Partners in April 2018, he has played a key role in advancing the firm’s financial due diligence practices and has remained closely involved in assessing financial and tax risks across the portfolio. Published education: B.A., English Language and Literature, Korea University. The primary profile’s career/background list names EY Han Young / KICPA; undated entries are not independently verified concurrent appointments. Published areas: Risk Management, Internal Audit, Financial Due Diligence. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Yujoung Kim (김유정) is published in Korea Investment Partners’ current Risk Management Partners directory as Manager. Yujoung is a Manager in the Risk Management Office at Korea Investment Partners, where she is responsible for financial due diligence and accounting reviews across the firm’s investment portfolio. She assesses the financial condition of portfolio companies from an independent perspective and uses financial data and analysis to identify risks relevant to investment decisions. A Korean Certified Public Accountant, she worked at Samil PwC before joining Korea Investment Partners, gaining experience in external audit and financial analysis across a range of companies. Her accounting and financial expertise now informs her assessment of portfolio companies and the financial risks underlying KIP’s investments. Published education: B.A., Economics, Sungkyunkwan University. The primary profile’s career/background list names Samil PwC / KICPA; undated entries are not independently verified concurrent appointments. Published areas: Risk Management, Internal Audit, Financial Due Diligence. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Ellie Dongwon Sung (성동원) is published in Korea Investment Partners’ current Venture Partners directory as Principal. Ellie began her career as a Data Scientist at SK hynix and later worked as an AI Research Fellow at SK Innovation, gaining hands-on experience applying data and AI to solve problems in the semiconductor and energy industries. She transitioned into venture capital to take a more direct role in bringing new technologies to market and supporting their growth. She focuses on emerging technologies including AI and the teams building new markets around them. With practical experience in semiconductors and AI, Ellie evaluates both the technical feasibility and scalability of emerging technologies and works closely with promising teams as they build and grow their businesses. Published education: B.S., Statistics and Economics, University of Illinois at Urbana-Champaign. The primary profile’s career/background list names SK Innovation, SK Hynix; undated entries are not independently verified concurrent appointments. Published areas: AI, DeepTech, Quantum. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Haksung Chang (장학성) is published in Korea Investment Partners’ current Private Equity Partners directory as Head of PE Division. Haksung is Head of the PE Division at Korea Investment Partners, where he leads the division’s investment strategy across IT, consumer, and manufacturing. He evaluates investment opportunities across company fundamentals, industry structure, transaction design, and downside risk. His notable investments include E-Land Retail, Carelabs, and Revu Corporation. Before joining Korea Investment Partners, Haksung worked at Eugene Asset Management, Macquarie International Ltd., and Samil PwC, building experience across asset management, investing, accounting, and finance. This background informs an investment approach that considers individual companies alongside broader industry structures and capital market conditions. Published education: B.A., Economics, Seoul National University. The primary profile’s career/background list names Samil PwC / KICPA, Macquarie International Ltd, Eugene Asset Management; undated entries are not independently verified concurrent appointments. Published areas: IT, Consumer, Manufacturing. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jiyun Kim (김지윤) is published in Korea Investment Partners’ current Venture Partners directory as Principal. Jiyun has built her career across accelerators, CVCs, and securities firms, including Sunbo Angel Partners, Musinsa Partners, and KakaoPay Securities, gaining exposure to companies at various stages of growth. This breadth of experience has shaped how she evaluates founders and companies through the lens of both markets and capital. She invests across consumer, IT, and deep tech, focusing on fundamentals and execution over narrative. She believes in the ability of ambitious founders and differentiated technology to create meaningful change, and aims to be more than a capital provider by supporting teams as they turn potential into scalable businesses. Published education: B.A., International Studies and Venture Management, Ewha Womans University. The primary profile’s career/background list names Sunbo Angel Partners, Musinsa Partners, KakaoPay Securities; undated entries are not independently verified concurrent appointments. Published areas: ICT, Consumer, Deeptech. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Junseok Oh (오준석) is published in Korea Investment Partners’ current Venture Partners directory as Principal. Junseok began his career at NH Investment & Securities, where he worked across equity research and IPOs. His experience advising companies as they prepared to go public gave him direct exposure to their growth and development, and ultimately led him to venture capital, where he could engage with companies at an earlier stage. He focuses on semiconductors, IT components and materials, and industrial automation—sectors where deep technical capabilities form the foundation of competitiveness. Rather than focusing on near-term performance alone, Junseok looks for companies with structural and sustainable competitive advantages and core capabilities that can strengthen and compound over time. Published education: B.B.A., Business Administration, Sungkyunkwan University. The primary profile’s career/background list names NH Investment & Securities, Samsung Securities; undated entries are not independently verified concurrent appointments. Published areas: IT Convergence, MPE, Semiconductor. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Junyoung Baek (백준영) is published in Korea Investment Partners’ current Private Equity Partners directory as Director. Junyoung is a Director on PE Team 1 at Korea Investment Partners, where he focuses on technology-driven investments across AI, robotics, and ICT. He evaluates business models, industry structure, competitive positioning, and potential paths to scale when assessing investment opportunities. He began his career at Hyundai Samho Heavy Industries, gaining firsthand experience in manufacturing operations, and later worked on IPO transactions at Kyobo Securities. He subsequently continued his career in investment management, including at History Investment Advisory, building a perspective that combines operating businesses with capital markets and investing. Published education: B.B.A., Business Administration, University of Seoul M.B.A., Fudan University (Dual Degree with Korea University). The primary profile’s career/background list names HD Hyundai Samho, Kyobo Securities, History Investment Advisory; undated entries are not independently verified concurrent appointments. Published areas: AI, Robotics, ICT. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Sangjoon Park (박상준) is published in Korea Investment Partners’ current Private Equity Partners directory as Head of PE Team 2. Sangjoon is Head of PE Team 2 at Korea Investment Partners, where he focuses on growth capital investments across energy and infrastructure, AI and robotics, and ICT services. He evaluates opportunities based on management execution, global scalability, market growth, and future potential that may not yet be fully reflected in a company’s current valuation. Before moving into private equity and venture capital, Sangjoon worked at Monitor Group Korea and GS Holdings in corporate strategy and portfolio management. He joined Korea Investment Partners as a founding member of the PE Division and has since contributed to growing the division’s assets under management to more than KRW 1 trillion and expanding its portfolio across a broader range of sectors and growth stages. Published education: B.B.A., Business Administration, Yonsei University. The primary profile’s career/background list names GS Holdings, Monitor Group Korea; undated entries are not independently verified concurrent appointments. Published areas: IT, Energy, Resources. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Soohyun Lee (이수현) is published in Korea Investment Partners’ current Venture Partners directory as Associate. Soohyun built her career scaling services across diverse categories, launching and growing a global platform at SNOW, leading the early-stage growth of Karrot’s Canadian business, and helping scale a global webtoon platform at RIDI. She transitioned into venture capital to create broader impact at the industry level beyond the growth of individual products. She invests in early- and growth-stage companies across content and IT services, evaluating opportunities based on team differentiation and execution, market potential, and scalability. She closely follows evolving user behavior and industry dynamics within the content ecosystem, with a particular interest in teams that can demonstrate tangible growth in the market. Outside of investing, she stays connected with industry practitioners and explores emerging content and cultural trends through performances and travel. Published education: B.B.A., Business Administration / B.A., Information Science and Culture, Seoul National University. The primary profile’s career/background list names SNOW Corporation, Danggeun Market (Karrot), RIDI Corporation; undated entries are not independently verified concurrent appointments. Published areas: Media, Contents, Entertainment. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Soonoh Ga (가순오) is published in Korea Investment Partners’ current Venture Partners directory as Principal. Soonoh began his career in the Strategy & Planning Division at SK Bioscience. He then spent five years in the IPO divisions of Daishin Securities and KB Securities, working on listings including Kakao Pay, HD Hyundai Marine Solution, Doosan Robotics, Jeju Beer, and Sandoll. His hands-on experience guiding companies through the IPO process led him to venture capital, where he could become involved earlier in their growth. Having worked with companies across the journey from early growth to IPO, Soonoh approaches the challenges facing startups through a capital markets lens. He favors companies with differentiated competitive advantages in industries undergoing structural change and invests across deep tech, mobility, and ICT platforms from Series A through Pre-IPO. His capital markets experience is particularly relevant to growth-stage companies preparing for a future listing. Published education: B.Sc., International Management, University of Manchester. The primary profile’s career/background list names SK Bioscience, Daishin Securities, KB Securities; undated entries are not independently verified concurrent appointments. Published areas: DeepTech, Mobility, ICT. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Taewoo Nam (남태우) is published in Korea Investment Partners’ current Private Equity Partners directory as Head of PE Team 3. Taewoo is Head of PE Team 3 at Korea Investment Partners, where he leads growth equity, significant minority, and buyout investments with a particular focus on the global competitiveness of Korean manufacturing and industrial companies. His investment experience includes Air Zeta, Chips&Media, and Oasis, together with board participation at portfolio companies. He has approximately 18 years of investment experience spanning both LP and GP roles. At the Public Officials Benefit Association, he managed domestic and international private equity portfolios, selected fund managers, and participated in co-investments. He joined Korea Investment Partners in 2019 to become more directly involved in investment decisions and portfolio company growth, and now brings both LP and GP perspectives to his investment approach. Published education: B.A., Economics and Public Administration, Hanyang University M.B.A., National University of Singapore. The primary profile’s career/background list names Public Officials Benefit Association (POBA), Alpha Asset Management, Daishin Securities, Opeaz Investment, Axis Investment, CNK Investment, History Investment Advisory; undated entries are not independently verified concurrent appointments. Published areas: ICT, Manufacturing, Materials. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Youngtak Lee (이영탁) is published in Korea Investment Partners’ current Private Equity Partners directory as Head of PE Team 4. Youngtak is a Director on PE Team 4 at Korea Investment Partners, where he invests across ICT, manufacturing, and materials, parts, and equipment through transaction structures including buyouts and mezzanine investments. He considers broader industry dynamics and structural market growth alongside company-specific fundamentals. Before joining Korea Investment Partners, he spent several years in Deal Advisory at Samjong KPMG and Deloitte Anjin, working on transaction structuring and execution across a range of industries. His experience analyzing financial profiles and competitive positioning led him to move from advisory to the buy-side and take direct responsibility for investment decisions. Published education: B.B.A., Business Administration, Yonsei University. The primary profile’s career/background list names Deloitte Anjin / KICPA, KPMG Samjong; undated entries are not independently verified concurrent appointments. Published areas: ICT, Manufacturing, MPE. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Donghyun Song (송동현) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Donghyun began his career as an engineer, working as a researcher at KIST and later as a principal researcher at Samsung Display. With a background in materials science and engineering, he transitioned into venture capital to work more closely with companies that can make a tangible contribution to industry and to participate in their growth over the long term. He focuses on deep tech and materials, parts, and equipment, evaluating companies based on the structural competitiveness of their technologies and their potential impact on industry. Donghyun pays particular attention to teams tackling problems that remain unsolved and to whether their technologies can translate into meaningful value in real industrial applications. Published education: Ph.D., Materials Science and Engineering, Seoul National University. The primary profile’s career/background list names Korea Institute of Science and Technology (KIST), Samsung Display; undated entries are not independently verified concurrent appointments. Published areas: IT, MPE, Materials. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Eunjae Jung (정은재) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Eunjae developed a deep understanding of pharmaceutical and biopharmaceutical technologies through academic research and hands-on experience at Chong Kun Dang’s DDS laboratory. His interest gradually expanded from the science itself to how new technologies can be developed into viable products and businesses, which led him to venture capital. He invests across stages in bio and healthcare, with a focus on the competitiveness of core technologies and their potential for commercialization. Eunjae is particularly interested in companies that can bridge the gap between scientific innovation and the market, turning promising research into products and businesses with real-world relevance. Published education: Ph.D., Pharmacy, Seoul National University. The primary profile’s career/background list names Chong Kun Dang Pharmaceutical / Pharmacist; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hangil Son (손한길) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Hangil has a scientific background in cell biology and pharmacology and gained hands-on clinical development experience at Hanmi Pharmaceutical, where he worked across the scientific and clinical aspects of drug development. He moved into venture capital to take a more direct role in the commercialization of innovative technologies and has since built a portfolio spanning multiple drug modalities and aesthetic healthcare. Hangil invests across stages from early to growth, with a focus on bio and healthcare, aesthetics, and general-purpose AI platforms. His experience in pharmacology and clinical development informs his evaluation of emerging technologies, including novel mechanisms of action, longevity, and AI integration. He focuses on companies with strong scientific foundations and the potential to lead meaningful technological shifts. Published education: Ph.D., Cell Biology / Pharmacology, Yonsei University. The primary profile’s career/background list names Hanmi Pharmaceutical; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Heejin Kim (김희진) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Heejin began his career as a semiconductor engineer at Samsung Electronics before moving to Partners Investment, where he gained investment experience and witnessed firsthand how technology and capital can come together to reshape industries. Rather than following a more predictable path, he was drawn to venture capital by the opportunity to work alongside founders creating new value amid uncertainty. He looks for founders with ambitions beyond building unicorns toward creating the next generation of decacorns, and takes a people-first approach to investing from the earliest stages. He focuses on the vision and execution of founding teams, as well as their potential to reshape markets at a structural level, and strives to be a long-term partner who listens closely to the voices of founders. Beyond investing, he also hopes to one day create something in his own way that resonates with people. Published education: B.S., Advanced Materials Science and Engineering, Korea University. The primary profile’s career/background list names Samsung Electronics, Partners Investment; undated entries are not independently verified concurrent appointments. Published areas: IT, Mobile, Semiconductor. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jihoon Jung (정지훈) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Jihoon has a background in biotechnology and worked in clinical and medical affairs at Novartis, where he gained firsthand experience in how innovative technologies are brought into clinical practice. He joined Korea Investment Partners to take a more direct role in turning scientific potential into viable businesses and now focuses on identifying innovative companies across bio, healthcare, and AI. Jihoon primarily invests in Series A–B companies, evaluating opportunities based on the scientific validity of core technologies, the expertise and execution capabilities of founding teams, and the clarity of their go-to-market strategies. Beyond providing capital, he works closely with companies to help translate strong R&D capabilities into sustainable commercial growth. Published education: Ph.D., Biotechnology, Yonsei University. The primary profile’s career/background list names Novartis Korea; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jihyun Ahn (안지현) is published in Korea Investment Partners’ current Venture Partners directory as Principal. Jihyun studied biological sciences with a strong interest in how science and technology can translate into real-world impact. She later worked at the Ministry of Science and ICT, where she was involved in science and technology policy planning and R&D programs in pharmaceuticals and precision medicine. Her interest in working closer to the commercialization of emerging technologies eventually led her to venture capital. With a background in biology, Jihyun primarily invests in bio and healthcare while also exploring opportunities across AI, robotics, content, and other technology-driven sectors. She looks for teams that can identify fundamental problems, develop effective solutions, and respond quickly to market feedback while navigating uncertainty. Published education: B.S., Biological Sciences, Seoul National University. The primary profile’s career/background list names Aju IB Investment, Ministry of Science and ICT; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jisoo Lee (이지수) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Jisoo began her venture capital career at Michigan Venture Capital, driven by a desire to contribute to the growth of the content industry through investment rather than as a creator herself. She later joined Magna Investment before moving to Korea Investment Partners, where she now leads the firm’s content investments as the lead fund manager of the "Korea Investment Global Content Fund" I and II. She focuses on identifying IP and creative teams with the potential to compete in global markets and supporting the international expansion of K-content. Jisoo places particular emphasis on the passion, commitment, and execution capabilities of management teams, and favors companies pursuing new ideas and strategies rather than simply repeating established formulas. Published education: B.A., Geography, Seoul National University B.A., Psychology, Oberlin College. The primary profile’s career/background list names ePNIC / Infineon Technologies, Michigan Venture Capital, Magna Investment; undated entries are not independently verified concurrent appointments. Published areas: Media, Contents, Entertainment. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Michael Kyowook Lee (이교욱) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Michael began his career as a software engineer at Microsoft, where he contributed to the development of Windows Live ID. He later co-founded mobile gaming startup Loadcomplete and served as CIO, leading the company’s technology organization and product development. He then joined Samsung Electronics, where he worked in product and business strategy and gained experience bringing technology into products and markets. These experiences ultimately led him to venture capital. Michael invests across early- and growth-stage companies, with a particular focus on robotics and AI. He looks for opportunities where differentiated technologies can open new markets or reshape existing industries, and focuses on teams with strong technical capabilities and the execution needed to scale. He works closely with founders who can continue building durable competitive advantages as technologies and markets evolve. Published education: M.S., Computer Science, Case Western Reserve University M.B.A., Columbia Business School. The primary profile’s career/background list names Microsoft, Loadcomplete, Samsung Electronics; undated entries are not independently verified concurrent appointments. Published areas: IT, AI, Game. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Soonouk Jung (정순욱) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Soonouk brings a multidisciplinary perspective across technology, business, and law, supported by his engineering background and qualification as a patent attorney. Working closely with Korea Investment Partners’ U.S. office, he has been involved in cross-border deal sourcing in Silicon Valley, connecting Korean institutional capital with the global venture ecosystem. This experience has deepened his understanding of technical barriers to entry and structural competitive advantages, while strengthening his interest in the commercialization of emerging technologies. Soonouk evaluates investment opportunities based on technical barriers to entry, structural competitive advantages, global scalability, and the domain expertise and execution capabilities of founders. Rather than following market trends, he focuses on a more fundamental question: "Why this team, with this technology architecture, can build a lasting advantage in this market at this point in time" Published education: B.S., Chemical and Biological Engineering, Seoul National University M.S., Management, KAIST LL.M., Northwestern University Pritzker School of Law. The primary profile’s career/background list names Industrial Bank of Korea / Patent Attorney, Jungang Law Firm, Melfas; undated entries are not independently verified concurrent appointments. Published areas: AI, Healthcare, IT Service. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Stephanie Seunghi Kang (강승희) is published in Korea Investment Partners’ current Venture Partners directory as Director. Stephanie spent seven years at Samsung Life Insurance, where she worked across overseas bond investments, international private equity investments, and investor relations. Her interest in working more closely with companies as they grow led her to join Korea Investment Partners in 2011, where she has since invested across a broad range of sectors. Stephanie approaches investing with a strong curiosity for new ideas and unfamiliar perspectives, an outlook she also carries into her travels and experiences outside of work. She values founders and teams that can create a positive impact and makes a conscious effort to avoid becoming too narrow in how she views markets and industries. More recently, she has found herself thinking deeply about how to raise children in a rapidly changing world, a question that also influences how she considers the future of industries and businesses. Published education: B.A., Political Science and International Relations, Korea University. The primary profile’s career/background list names Samsung Life Insurance; undated entries are not independently verified concurrent appointments. Published areas: IT, Media, Contents. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Deokjun Shin (신덕준) is published in Korea Investment Partners’ current Venture Partners directory as Investment Advisory. Deokjun began his career at Samsung Electronics’ Semiconductor Memory Division, where he worked on the design and development of flash memory circuits. He entered the venture capital industry in 1999 and has since focused primarily on investments in semiconductors, IT, and related technology sectors. Since joining Korea Investment Partners in 2006, he has invested in companies including Haesung Optics, Chips&Media, BOS Semiconductors, and FuriosaAI. Deokjun primarily focuses on early-stage technology companies and actively pursues co-investments in ventures with strong technical capabilities and clear technology roadmaps. Published education: M.S., Electronic Engineering, Sogang University. The primary profile’s career/background list names Samsung Electronics, KTB Network, VirtualDime, Hallym Ventures, Hanwha Investment; undated entries are not independently verified concurrent appointments. Published areas: IT, Semiconductors, Medical Devices. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Dongyeob Kim (김동엽) is published in Korea Investment Partners’ current Management Executives directory as CIO. Dongyeob earned his bachelor's degree in Literature from Seoul National University, and chose Korea Investment Partners as his first career step, entering the world of venture capital early on. Drawing on the broad perspective and critical thinking cultivated through his literary background, he has built deep investment expertise spanning diverse industries — including TMT, biotech, and gaming. Having grown alongside a single organization over many years, he has established himself as the leader who most fully embodies KIP's investment philosophy and culture. Building on a strong track record of successful investments, he currently serves as the Lead Fund Manager of Korea Investment Partners' flagship funds, consistently delivering outstanding fund performance through his professional expertise in fund management. In particular, he has pioneered a wide range of investment strategies — from early-stage investing to mezzanine investments in listed companies — and now leverages this experience to lead Korea Investment Partners' diversified investment strategy. Published education: B.A., German Language and Literature, Seoul National University. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Consumer, Mobile, Contents. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Hwamok Chung (정화목) is published in Korea Investment Partners’ current Venture Partners directory as Managing Director. Hwamok built his career across Hyundai Commercial and the LG Foundation, gaining experience across both finance and the nonprofit sector. His exposure to different organizations and industries has shaped a broad perspective on markets, consumers, and emerging trends, which he now applies to venture investments across IT, AI, consumer, and content. He focuses on investing in founders and entrepreneurs who are working to improve people's lives today or just ahead of the curve, shift existing industry problems in a positive direction or expand into new industries, and capture the spirit of the times through IP and content. Published education: B.B.A., Business Management, Yonsei University M.B.A., Seoul National University. The primary profile’s career/background list names Hyundai Commercial, LG Foundation; undated entries are not independently verified concurrent appointments. Published areas: Contents, Consumer, IT Service. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Jin Huh (허진) is published in Korea Investment Partners’ current Venture Partners directory as Head of Investment Division 1. Jin built his experience in corporate analysis at Samil PwC and KB Asset Management, developing a strong understanding of financial statements, business fundamentals, and growth companies. As a Korean Certified Public Accountant, he brings a disciplined analytical perspective to investing, with a focus on companies operating in attractive markets and demonstrating clear competitive differentiation. Jin primarily invests in mid- to late-stage companies across materials, parts and equipment, and consumer sectors. His notable investments include Nextin, CMTX, NB Motion, Cafe24, and Millie’s Library. He evaluates opportunities based on market growth potential as well as the technological and business advantages that differentiate a company from its competitors. Published education: B.B.A., Business Administration, Chung-Ang University. The primary profile’s career/background list names Samil PwC / KICPA, KB Asset Management; undated entries are not independently verified concurrent appointments. Published areas: IT Convergence, MPE, Contents. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Kunho Kim (김근호) is published in Korea Investment Partners’ current Venture Partners directory as Managing Director. Kunho spent six years at Samil PwC, working across audit and deal advisory and developing a deep understanding of corporate financials and business structures. His interest gradually shifted from analyzing past performance to working more closely with companies as they build future growth and innovation, leading him to transition into venture capital. He focuses on growth-stage investments in technology-driven companies with clear differentiation, evaluating scalability and competitive positioning as key factors. Beyond the initial investment, Kunho works closely with portfolio companies on their growth and potential exit pathways, including IPOs and M&A. Published education: B.A., Economics, Seoul National University. The primary profile’s career/background list names Samil PwC / KICPA; undated entries are not independently verified concurrent appointments. Published areas: IT Service, IT Convergence, Consumer. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Mahnsoon Hwang (황만순) is published in Korea Investment Partners’ current Management Executives directory as CEO. Mahnsoon earned his bachelor's and master's degrees in Pharmacy from Seoul National University, then began his career as an R&D researcher at Yuhan Corporation. He went on to serve as Vice President at both Yuhan Corporation and ChemOn, building deep expertise in biotech and healthcare through hands-on experience ranging from new pipeline development to clinical-stage trials. Drawing on this industry background, he recognized greater potential in the role of a venture capitalist — supporting promising biotech companies with capital and strategy to help them grow. This realization led him to Korea Bio Technology Investment, and subsequently to Korea Investment Partners, which he joined in 2009. A veteran investor with a track record spanning investments in promising biotech companies both in Korea and abroad, he has experience seeing portfolio companies through to IPOs and M&A exits not only domestically but internationally as well, and currently manages a cumulative fund of over KRW 700 billion. As both a VC investor and a leader in Korea's biotech industry, he is active across a wide range of initiatives — achievements for which he received a Presidential Citation in 2025. Published education: M.S., Pharmacy, Seoul National University. The primary profile’s career/background list names Yuhan Corporation, Korea BioTechnology Investment, CHEMON, Affiliated Professor for Ewha Womans Univ. Medical Center(Clinical Trials), Chairman of New Industry Organization for Investment, Member of K ARPA-H; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Min Q Kim (김민규) is published in Korea Investment Partners’ current Venture Partners directory as Managing Director. Min Q began his career in control and instrumentation engineering, building hands-on experience in developing and commercializing advanced technologies. At SoftDSP, he developed a USB-based 5 GS/s PC oscilloscope that was exported to more than 10 countries. He later worked as a Senior Researcher at Samsung Electronics and the Samsung Advanced Institute of Technology, where he focused on ultra-low-power wireless communication technologies and registered more than 15 patents. His experience taking technologies from development through commercialization and into global markets led him to venture capital. He focuses on strategic deep-tech investments across quantum computing, blockchain and Web3, energy, and other emerging technology sectors, with investment experience in the U.S. and Israel. Combining 18 years of venture investing with an engineering background, he evaluates both the technical foundations and commercialization potential of emerging technologies and looks for core technologies capable of driving structural change across industries. Published education: Ph.D. Candidate, Electrical and Computer Engineering, Seoul National University. The primary profile’s career/background list names SoftDSP, Samsung Advanced Institute of Technology, Samsung Electronics; undated entries are not independently verified concurrent appointments. Published areas: AI, Deep Tech, Quantum. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Minsik Park (박민식) is published in Korea Investment Partners’ current Venture Partners directory as Head of Investment Division 2. Minsik began his career at Daewoo Electronics after studying Business Administration at Korea University, where he gained firsthand exposure to consumer markets and the manufacturing industry. He later built his investment career at Mirae Asset Venture Investment and Mirae Asset Securities, focusing on internet, mobile, and consumer sectors. His interest in identifying innovative companies and supporting their growth in a rapidly evolving digital consumer landscape led him to join Korea Investment Partners. As Head of Investment Group 2, he oversees both domestic and international investments at KIP. He also serves as Global Head, leading the firm’s overseas investment activities and broader global investment strategy. Drawing on extensive fund management experience, he serves as Lead Fund Manager of KIP’s National Growth Fund, its 2026 flagship fund, and plays a central role in KIP’s evolution into a global venture capital firm through its domestic and international investment activities. Published education: B.A., International Trade, Korea University. The primary profile’s career/background list names Daewoo Electronics, MiraeAsset Ventures, MiraeAsset Securities; undated entries are not independently verified concurrent appointments. Published areas: IT, Mobile, Consumer. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Sujin Kim (김수진) is published in Korea Investment Partners’ current Venture Partners directory as Managing Director. Sujin began her career in the gaming and content industry at NCSOFT before moving into venture capital. Her hands-on operating experience gives her a practical perspective on identifying and supporting companies with strong growth potential across content, software, and gaming. She focuses on businesses where technology and intellectual property can create new opportunities for scale, particularly across content and gaming. Sujin looks for teams with strong execution capabilities and a clear path to commercialization, with a focus on how content and technology can build lasting value in the market. Published education: M.B.A., Business Administration, Ewha Womans University. The primary profile’s career/background list names EK Communication, NC Soft, SK imedia, GSP, YD Online, Neowiz Games; undated entries are not independently verified concurrent appointments. Published areas: Contents, Software, Game. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Yeongmok Gil (길영목) is published in Korea Investment Partners’ current Venture Partners directory as Managing Director. Yeongmok has built an unconventional career spanning equity research, fund management, consulting, and investor relations and disclosure at listed companies. This breadth of experience gives him a differentiated perspective on both identifying investment opportunities and structuring exits. He has led investments across biotechnology, secondary transactions, and mezzanine deals involving listed companies. He primarily invests from Series B onward and takes a sector-agnostic approach. Guided by the belief that great companies are built by great management teams, he places particular emphasis on the quality of management and the soundness of their decision-making. He also identifies more closely with Charlie Munger’s philosophy of sharp, disciplined thinking behind the scenes than with Warren Buffett’s more publicly visible optimism, and brings that perspective into his investment decisions. Published education: B.S., Biochemical Engineering, KyungHee University. The primary profile’s career/background list names FnGuide, Herb Doctor International, Bio Partners, Prodizen, CKD Venture Investment; undated entries are not independently verified concurrent appointments. Published areas: Bio, Consumer, Secondary. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.

Rivus Batteries is the Gothenburg company Rivus AB, developing aqueous organic electrolytes for stationary flow batteries. Its chemistry stores energy using organic molecules, water and salts rather than critical-metal electrolytes such as vanadium, with the goal of supporting long-duration renewable-energy storage and more resilient supply chains. It designs the electrolytes to work with existing commercial flow-battery hardware and industrial chemical production, rather than requiring proprietary battery stacks. Its commercialization effort began in early 2023, following research at Chalmers, the University of Turku and the Technical University of Denmark. The company is advancing chemical scale-up, stack testing and customer pilots during 2026–2027; its 2028 large-scale deployment objective is a target. Lower costs, safety and performance advantages are company development claims, rather than independently proven outcomes of widespread commercial deployment.

Andreas Kölling co-founded Rivus and leads operations. An MBA graduate with management, sales and strategy experience, he joined the commercialization effort in early 2023.

Arsema Andemariam joined Rivus for a master’s thesis supporting lab testing and research, as announced in April 2025. The issuer identifies her as a chemical engineer studying materials chemistry at Chalmers. No current employment or thesis end date is inferred.

Cedrik Wiberg founded Rivus and leads its battery technology and business. He earned a doctorate in electrochemistry at Chalmers and conducted postdoctoral work at the Technical University of Denmark and the University of Turku. His organic flow-battery research began in 2016.

Eduardo Maurina Morais leads Rivus’ research and development. He trained in chemistry in Brazil and earned a materials-science doctorate at Chalmers, researching ionic liquids. He helped build the company’s laboratories, testing capabilities and chemistry team after joining in January 2024.

Henrik Sundén advises Rivus on technology and scientific chemistry. He is a University of Gothenburg chemistry professor researching methods for making organic molecules and chemical bonds.

Johan Hjelm advises Rivus on technology. The issuer identifies him as a professor and section head in energy conversion and storage at the Technical University of Denmark.

Johan Söderbom is a Rivus board member. The issuer describes his energy-storage investment and research experience, including a thematic-leader role at EIT InnoEnergy and engineering-physics training.

Lars Ulin chairs Rivus’ board. The issuer identifies him as owner and managing director of NAVCAP, investing in Swedish industrial businesses and startups.

Lisa Åkerlund was announced as Rivus’ Chief Technology Officer in February 2024. She earned a doctorate researching organic batteries at Uppsala and has battery-industry, project-management and sustainability experience. She is absent from the current named management directory; no departure date is inferred.

Narendiran Raveendiran works on battery building, testing and reporting at Rivus. He holds a joint renewable-energy engineering master’s from KTH and UPC, and researched electrolyte pH and stability in his company thesis. A February 2026 issuer announcement described his move from thesis and internship work into a full-time Lab Engineer role; the current directory uses Lab Technician.

Niclas Davidsson is a Rivus board member with engineering and business-development experience. The issuer describes him as Meva Energy’s CEO and an industrial-engineering graduate.

Pekka Peljo advises Rivus on technology. The issuer describes his materials-engineering research at the University of Turku, specializing in energy storage and flow batteries.

Rickard Arvidsson supervised a company-linked master’s project evaluating hazards of organic flow-battery molecules using QSAR machine-learning models. Rivus identifies him as an associate professor in Environmental Systems Analysis at Chalmers. This is an external study affiliation, not employment or governance.

Robert Scholem supports Rivus’ laboratory operations and holds a master’s degree in renewable energy engineering.

Sara Hjortmar advises Rivus on business. The issuer describes her investment and asset-management work at EIT InnoEnergy and commercial experience in startups and scaleups.

Tamara Church works on scaling Rivus’ electrolyte synthesis from laboratory and prototype results to reliable industrial processes. She earned an organic-chemistry doctorate at Cornell and has worked in academic chemistry, carbon-capture research and pharmaceutical process chemistry, including Cambrex.

Viktor Gueskine is Rivus’ Lead Scientist, contributing four decades of chemistry and research-and-development experience to its battery program.

Novarna, legally CircNova, Inc., designs RNA molecules for biotechnology and pharmaceutical research partners. Its NovaEngine generative AI predicts RNA structures and generates new sequences, while its Ann Arbor NovaLab synthesizes candidates, measures their activity and feeds experimental results back into the model. Starting with circular RNA, the company now describes work across several RNA modalities, including microRNA sponges, aptamers and RNA-based protein degradation. Partners bring a biological target and indication; the company designs and validates candidates, with program intellectual property belonging to the partner and platform methods retained by Novarna. It reports proof of concept in ovarian cancer cell models tested by the University of Michigan’s DiFeo Lab; these laboratory results are not clinical efficacy or approved medicines. Its broader discovery interests include neurological diseases and rare disorders. NovaEngine Nexus, integrating aptamer design with SHAPE and SELEX experimental data, is described as in development. The company has a Cambridge, Massachusetts headquarters and Ann Arbor wet lab. CircNova changed its brand to Novarna in August 2026 while retaining the same legal company, agreements and programs.

Alex Wesselhoeft leads Novarna’s RNA research. He developed RNA circularization technology during his MIT doctoral work and co-founded ORNA Therapeutics. The company publishes his Mass General Brigham RNA core and Harvard Medical School teaching background.

Cindy Warner leads Novarna’s operations, finance and commercial execution. Her published background spans technology and consulting at FedEx, EY, PwC, IBM and Salesforce, and founding 360ofme.

Crystal Brown leads Novarna’s strategy, partnerships and fundraising. She previously worked in operations at automotive and finance companies, served as business operations director at Ocuphire Pharma and co-founded Great Lakes Biologics.

Joe DeAngelo advises Novarna on scientific strategy and circular RNA therapeutics. His published background includes founding Apex Bioscience, development leadership at Curacyte and former leadership of Neochromosome. Earlier CircNova publications identify him as chief scientific officer.

Brent Jiang joined Omega as Vice President of Investor Relations in 2025 after working at Wellington. He holds a Boston University business degree and an MIT MBA.

Denise Kiley joined Omega as an Executive Assistant in 2023, supporting Bernard Davitian and Michelle Doig. Her experience includes operating a small business and 15 years at State Street. She holds a Bridgewater State education degree.

Estelle Decosterd has worked as an Omega Executive Assistant in Geneva since 2018. Her previous experience includes NeoMed, Kellogg and Procter & Gamble. She trained in business at Lycee Jean-Piaget.

Gilchrist DiPrete returned to Omega in 2023 as Director of Investor and Portfolio Analytics after serving as Assistant Controller from 2018 to 2022. His earlier experience includes Clean Energy Ventures, PwC, Benefit Street and Vista. He holds University of Rhode Island degrees.

Heather Weekley joined Omega in 2018 and is Operations Manager. She previously worked at Horizons for Homeless Children and holds public-administration and political-science qualifications from Bridgewater State.

Jonathan Hempton joined Omega as Deputy General Counsel in 2025 after corporate-transaction work at Ropes & Gray. He holds an NYU law degree, a Fletcher international-affairs degree and a Boston University business degree.

Kaitlyn Hagins joined Omega as an Operations Assistant in 2026. She studied business at Northeastern with concentrations in finance and international business.

Lindsay Shean joined Omega as an Operations Coordinator in 2024 after working in real-estate financial operations. She studied economics and psychology at Boston College.

Maria Koehler joined Omega as a Venture Partner in 2025. An oncology physician-scientist, she previously served as Chief Medical Officer of Repare from 2019 to March 2025 and held roles at Bicycle, Pfizer, AstraZeneca and GSK. She earned medical and doctoral degrees at Silesian Medical University.

Mark Russell joined Omega in 2010 and serves as Chief Compliance Officer and Vice President of Finance. His earlier career included Schooner and Bisys. He holds a Plymouth State degree and a Suffolk MBA.

Menelas Pangalos joined Omega as a Venture Partner in 2024. He led research and development at AstraZeneca from 2010 to 2024 after roles at Wyeth and GSK. His published biography describes academic and biotechnology board affiliations and his 2019 knighthood.

Philipp Bliedung joined Omega in 2018 and is Corporate Controller. He previously worked at a family office and PwC. His degrees include Furman undergraduate study and Northeastern accounting and business graduate qualifications.

Sanjaya Singh joined Omega as a Venture Partner in June 2023. His biotechnology career includes Janssen, Boehringer Ingelheim and Tanox, and cofounding Aliada Therapeutics. He holds a Banaras Hindu University doctorate and completed postdoctoral research at MD Anderson.

Susana Carella joined Omega as an Executive Assistant in 2025, supporting Otello Stampacchia. Her previous experience includes GALY, Atlas and Thomas H. Lee Partners. She holds a Boston University psychology graduate degree and a Montclair undergraduate degree.

Tara Kelly joined Omega as Senior Finance Manager in 2026 after serving alternative-investment clients at PwC. She holds a Northeastern business degree and is a certified public accountant.

Roshawn Blunt joined Omega as a Venture Partner in 2023. She is president of Corsaire and previously worked at 1798 Consultants, Amgen, Johnson & Johnson and Boston Consulting Group. She studied at Princeton and Kellogg.

Vincent Ossipow joined Omega as a Partner in 2014 after investment roles at NeoMed, Sectoral Asset Management and Pictet. His background combines molecular biology and computational science, including a University of Geneva doctorate. His published biography identifies an Anaconda Biomed board-observer affiliation.

Bernard Davitian joined Omega as a Partner in 2020. He previously served as Senior Vice President and Managing Director of Sanofi Ventures and held corporate leadership roles at Fovea Pharmaceuticals, Neurotech, Transgene and Institut Merieux.

Kurt Kongtong Gallagher joined Omega as an Associate in 2026. His previous experience includes venture fellowships and Harvard technology transfer. He holds a Harvard immunology doctorate and a Columbia undergraduate degree.

Michelle Doig joined Omega in 2016 and is a Partner and Head of Corporate Development. Her previous career included Third Rock Ventures, Abingworth and investment banking. She studied at the University of Western Ontario and Ivey Business School.

Noelle Hutchins joined Omega in 2020 and is a Principal focused on oncology and inflammatory diseases. Her previous experience included the American Heart Association, consulting and Pipeline Angels. She holds a Brown immunology doctorate and completed postdoctoral work at UT Southwestern.

Otello Stampacchia founded Omega Funds in 2004 and is a Managing Director and investment-committee member. His earlier career included AlpInvest, Lombard Odier, Goldman Sachs and Index. He trained in pharmacogenetics and molecular biology at Pavia and Geneva.

Deirdre Cunnane joined Omega in 2019 as Chief Operating Officer and General Counsel. She previously led legal affairs at Catabasis Pharmaceuticals, Advanced Technology Ventures and Lightstone Ventures, and worked in venture investing at BancBoston. She holds Boston College law and finance degrees.

Eric Cooper joined Omega Funds as Chief Financial Officer in 2026 after 28 years at ABRY Partners, where his senior finance responsibilities included fund accounting, compliance and investor reporting. He holds a University of Massachusetts finance degree and an MIT MBA.

César-Mateo Espert Rodríguez is recorded by the official mercantile bulletin as Innvierte’s non-director board secretary, appointed in May 2025. The same filing expressly identifies him as non-member secretary of the internal control and communication body. A secretary affiliation does not imply a board director or investor role.

Daniela Leal Vargas is recorded in the official mercantile bulletin as Innvierte’s non-director deputy board secretary, appointed in May 2025. This is a statutory secretarial affiliation rather than a board director or portfolio investment attribution; further public career details and an authentic portrait were not established in the reviewed sources.

Ana Isabel Vega Escudero is listed by Spain’s securities regulator as an Innvierte Economía Sostenible board member appointed on 28 February 2025. The March 2025 official mercantile bulletin also records her appointment. This is a source-scoped statutory governance affiliation, with further professional biography and authentic portrait not published in the reviewed registry.

Ana Isabel Villoria Gajate served on the Innvierte Economía Sostenible board in 2025. The official mercantile bulletin records her appointment in March 2025 and her cessation in an entry registered on 28 July 2025, alongside María Ángeles Cano Díaz’s appointment. Registry-entry dates are distinguished from exact effective appointment or departure days, which are not established for her by the reviewed sources. She is represented as a historical statutory director rather than part of the current CNMV roster.

María Ángeles Cano Díaz is listed by the CNMV as an Innvierte Economía Sostenible director effective 17 July 2025. The official mercantile bulletin records the appointment on 28 July 2025 after Ana Isabel Villoria Gajate ceased as a director. The effective appointment date and registry entry date are distinct; additional career history and authentic portrait remain unconfirmed.

María Antonia Scheifler Alácano is a statutory director of Innvierte Economía Sostenible, the self-managed state investment company owned by CDTI. The CNMV official register records her appointment on 27 February 2024. The CDTI programme page separately uses the shorter published name Marian Scheifler Alácano; that spelling discrepancy is retained in the institution source audit rather than creating a second assumed person. Additional career details and portrait are not confirmed by the reviewed legal register.

Álvaro Simón de Blas is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Anatolio Alonso Pardo is publicly identified by Spain’s European Funds administration as Deputy Director General for management of the European Regional Development Fund. He previously served as an Innvierte board member. The official mercantile bulletin records his cessation in an entry registered on 21 March 2025, despite the older CDTI web directory retaining his name. That registry-entry day is not asserted as his exact effective departure day.

Carmen Vela Olmo is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

César Ramos Villena is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Elisabet Roselló Román is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Laura Olcina Puerto is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Patricia Tamés Ortega is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Pedro Mier Albert is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Cecilia Medina Marín is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Daniel González Bootello is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Francisco Marín Pérez is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Joaquín Gómez Gómez is publicly identified by CDTI as Director of the Instituto de Fomento de la Región de Murcia (INFO) and is listed on its external strategic advisory council. He participates in public innovation-financing cooperation between INFO and CDTI. This is the Murcia institutional official, distinct from the existing Sherry Ventures investor with a similar shortened name.

José Manuel Leceta García is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Laura González-Estéfani is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Raquel Jorge Ricart is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Eduardo Cotillas Provencio is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Ignacio Cristóbal Sánchez is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Rocío Arroyo Arranz is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Soledad Díaz Campos is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Víctor Cruz Salgado is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Xavier Ferrás Hernández is publicly listed by CDTI in its external strategic advisory council. This consultative body provides expert guidance on innovation and monitors the 2024–2027 strategic plan; the affiliation is not a permanent agency staff position.

Cecilia Hernández Rodríguez is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Director of Industry Programmes, Agencia Espacial Española. This profile records that source-scoped public responsibility; additional career history is not inferred.

José Guimón de Ros is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Scientific Adviser to the Minister of Science, Innovation and Universities. This profile records that source-scoped public responsibility; additional career history is not inferred.

Justo Jorge Pagán Guillén is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Deputy Director General for Industrial Project Promotion, Ministry of Industry and Tourism. This profile records that source-scoped public responsibility; additional career history is not inferred.

María Isabel Pérez-Cerdá Herrero is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Head of Platforms and Robotics Unit, Ministry of Defence. This profile records that source-scoped public responsibility; additional career history is not inferred.

Nuria Valcárcel Sanz is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Head of Technical Cabinet, General Secretariat for Innovation. This profile records that source-scoped public responsibility; additional career history is not inferred.

Roi Villar Vázquez is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Senior Public Research Organisations Technician, Instituto de Salud Carlos III. This profile records that source-scoped public responsibility; additional career history is not inferred.

Antonio Alcolea Muñoz is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Deputy Director General for Programmes, Governance and Promotion, Directorate General for Data. This profile records that source-scoped public responsibility; additional career history is not inferred.

Francisco Javier Garzón Morales is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Deputy Director General for Communications, Ministry of Economy, Trade and Enterprise. This profile records that source-scoped public responsibility; additional career history is not inferred.

José Luis Calvo Labra is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Deputy Director General for Information and Communications Technologies, Ministry of Economy, Trade and Enterprise. This profile records that source-scoped public responsibility; additional career history is not inferred.

José María Ocón Alcoceba is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Head of European Funds Aid Management subdivision, Agencia Estatal de Investigación. This profile records that source-scoped public responsibility; additional career history is not inferred.

Lucía Díaz León is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Deputy Director General for Financial Administration and General Services, Ministry of Economy, Trade and Enterprise. This profile records that source-scoped public responsibility; additional career history is not inferred.

María Isabel Fernández Santos is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Adviser, Ministry of Science, Innovation and Universities Undersecretariat. This profile records that source-scoped public responsibility; additional career history is not inferred.

María Vega Gil Díaz is Economics and business graduate from Universidad del País Vasco, with financial-engineering and venture-capital training. Worked in audit at Argentaria and risk analysis at Extebandes before joining CDTI in1991. Led financial evaluation and financing/investment departments and is publicly listed as an ENISA board member.

Tomás Fraile Santos is publicly listed by CDTI in its governance directory. The published professional remit is Consejo Rector member; Technical Cabinet Adviser, Science and Innovation Undersecretariat. This profile records that source-scoped public responsibility; additional career history is not inferred.

Carlos de la Cruz Molina is Industrial engineer from Universidad Politécnica de Madrid with an international MBA and venture-capital training. Began in1987 at LCOE and worked as a project engineer at CLH before joining CDTI in1990. Held technology evaluation and departmental leadership posts; the current directory heading states Technology and Internationalisation, while its older biography retains the earlier Technical Evaluation title.

Javier Pérez Torrijos is Law graduate of Universidad Autónoma de Madrid with European Communities studies at ICADE, public-international-law research at UNED and corporate legal training at IE. Previously handled legal matters for the Innvierte capital-risk programme at CDTI, served as deputy legal adviser and board deputy secretary at SEPI, and spent over 20 years in CDTI legal services.

Juan Antonio Tébar Chumillas is Aeronautical engineer and international MBA graduate from UPM with leadership and innovation programmes at IESE, MIT, Comillas and ESADE. Worked on the A 400 M at EADS/CASA before joining CDTI in2008, progressing through European framework-programme leadership. Represents Spain in Horizon Europe and EIT policy bodies and sits on the ENSA board.

María Pilar Carrato Mena is Business graduate of CUNEF with financial and public-management training. Began as a Banco de España financial analyst and worked thirteenyears in private financial institutions before joining Spain’s senior state audit/intervention corps. Served as secretary general of ICAC and audited European funds at IGAE, joining CDTI in November2018.

Miguel Valle García is Economics graduate with morethan 20 years designing, managing and evaluating public R&D and innovation policy. Joined CDTI in2006 and worked in innovation promotion, studies, communications and strategy. Previously led strategy and evaluation, coordinating programmes including Misiones, Cervera and innovation-transfer ecosystems.

José Moisés Martín Carretero is Economist trained at Universidad Autónoma de Madrid, with postgraduate finance and computational-methods studies and executive training at MIT and INSEAD. Before directing CDTI he led consultancy Red 2 Red from 2014 and has more than 25 years of public/private experience. Previously managed multilateral cooperation at AECID and taught economics and technological entrepreneurship at Universidad Camilo José Cela from2016–2024.

Teresa Riesgo Alcaide is Spain’s Secretary General for Innovation and a professor of electronic technology at Universidad Politécnica de Madrid. She has directed its Industrial Electronics Centre and led research and international relations at its industrial engineering school. Her research covers embedded systems, reconfigurable hardware and Internet-of-Things electronics; she holds an industrial engineering doctorate from UPM.

TNBT Capital is a French family office and company-building investor led by Robert Picarel. Its current own legal notice identifies TNBT CAPITAL SAS, Paris RCS/SIREN887642593, at128 rue La Boétie,75008Paris. The French government's active-company registry gives legal creation July24,2020; the firm's own founder narrative describes the family-office investment activity as founded in2021. These are distinct legal and operating milestones. Its published model combines company creation, operational support, acquisitions, venture investing and private debt across healthcare, medical technologies and infrastructure. The own portfolio identifies adaptive brain-stimulation developer Newronika and stroke-device developer Anaconda Biomed, alongside Spiral Therapeutics, Askel Healthcare, ARTHA and other named projects. Newronika's February13,2025 primary issuer announcement identifies TNBT as an existing investor participating in its completed EUR13.6M SeriesB; TNBT's ticket and legal subscribing account are not public. Current own materials publish founder Robert Picarel but no comprehensive operating-staff directory. The legal notice's EUR18,007,357 corporate share capital is not an external LP fund close or cash raised; no publicly verified LP vehicle, closed fund size or investment allocation is invented. Current portfolio entries establish named relationships, not financing dates, product approvals or clinical efficacy.

Robert Picarel is the founder of TNBT Capital and the president named in the French active-company registry. TNBT's own biography describes software-engineering training followed by marketing and consulting work, then the co-founding of Velvet Consulting in2004 with a focus on customer strategy, data and digital transformation. WPP's September4,2020 acquisition announcement independently names him and Fabienne Magot as Velvet's founders. TNBT reports that he remained Velvet's non-executive chairman until2025 and developed the family-office activity in2021. His own advisory-board host describes earlier work at Capgemini and Nielsen and an engineering degree fromCYTech; these are source-attributed career details without invented employment or graduation days. Only his verified TNBT founder/president role is recorded here. The published adviser-card portrait is explicitly bound to his name and TNBT chairman biography.

Aleksandr Proskurin is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building the AI system; formal job title and current tenure are not established by that historical account.

Alexey Lazarev is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building the AI system; formal job title and current tenure are not established by that historical account.

Andrew Stepanov is published in QuantumLight’s current own team directory as Chief of AI.

Anton Trubakov is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building or supporting the business; formal job title and current tenure are not established by that historical account.

Artem Gogin is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building the AI system; formal job title and current tenure are not established by that historical account.

Chandler Kallas is published in QuantumLight’s current own team directory as Partner.

Christian Repole is published in QuantumLight’s current own team directory as Partner.

Dora Zikouli is published in QuantumLight’s current own team directory as Partner.

Elizabeth Morozova is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building or supporting the business; formal job title and current tenure are not established by that historical account.

Evgeny Obukhov describes his work as data science and machine-learning research at an AI-driven venture firm founded by Nik Storonsky, and lists QuantumLight in his published experience. His own profile shares the QuantumLight–Vento analysis of anonymized founder-program applicant assessments; current tenure is not independently established.

Ezio Mantegazza is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building or supporting the business; formal job title and current tenure are not established by that historical account.

Ilya Kondrashov is published in QuantumLight’s current own team directory as CEO.

Kate Chan is named as the Data Protection Officer in QuantumLight’s own privacy policy for Quantum Light Management Ltd. The policy identifies her as the contact for privacy questions and data-subject rights. It does not establish whether she is employed by the manager or provides the function externally, and no broader career identity is assumed.

Louis Fontaine is published in QuantumLight’s current own team directory as Partner.

Maryna Omelchenko is published in QuantumLight’s current own team directory as Partner - Fundraising.

Nik Storonsky is published in QuantumLight’s current own team directory as Founder. The same website identifies him as Revolut’s CEO and co-founder and describes the firm’s use of his operating playbooks.

Nikita Ovsov is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building the AI system; formal job title and current tenure are not established by that historical account.

Ruggero Pesciatini is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building or supporting the business; formal job title and current tenure are not established by that historical account.

Ruslan Sungatullin is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building the AI system; formal job title and current tenure are not established by that historical account.

Saveliy Tatarskikh is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building the AI system; formal job title and current tenure are not established by that historical account.

Stephanie Manz-Varga announced joining QuantumLight in London on October 30, 2025 to work with Series B and Series C founders. Her announcement names the investment and technical team she was joining; formal job title and current tenure are not established by this dated post.

Tommaso Conca is published in QuantumLight’s current own team directory as Partner.

Tommaso Pace is named in QuantumLight business-builder Ezio Mantegazza’s May21,2025 account of developing the firm and its investment platform. The source associates this person with building or supporting the business; formal job title and current tenure are not established by that historical account.

Anna Legg was Global Kinetics’ Chief Financial Officer before the company’s December2020 announcement of Thomas Ulmer’s appointment. The issuer expressly said she was stepping down to pursue other opportunities. Her historical financial leadership is recorded without assuming an exact final employment day or a current role within PKG Health/Empatica.

John Schellhorn was appointed President and CEO of Global Kinetics Corporation in October2017. The issuer’s own syndicated release describes more than thirty years in medical devices and prior leadership at Barrx Medical and Softscope Medical Technologies, which was acquired by Fujifilm. Subsequent PKG leadership sources identify different CEOs, so this is a historical role rather than a current post-acquisition appointment.

Andrew Maxwell was Global Kinetics Corporation’s Managing Director at its completed June2015 private placement. The issuer’s release describes his responsibility for international commercial expansion, manufacturing and introduction of the next PKG generation following regulatory clearances. This dated leadership is historical; later employment and current board tenure are not asserted.

Robert Griffiths is the technology co-founder identified alongside Malcolm Horne on PKG Health’s own company history. Their Parkinson’s KinetiGraph work underlies wearable movement measurement and reporting for clinical care and research. The archived issuer source establishes founder attribution, not current employment or a statutory director appointment; unrelated people named Robert Griffiths are not merged.

David Atkins joined Global Kinetics’ board in May2023 as a BioScience Managers representative. The manager’s October2022 biography describes his prior Congenica leadership and senior roles at Johnson & Johnson, Danaher and Medicover. His qualifications include a Columbia MBA, molecular-virology PhD at John Innes, UNSW pharmacology study and University of East Anglia biological-sciences degree. Later PKG board tenure following acquisition is not established.

Malcolm Horne is a neurologist and neuroscience researcher identified by Global Kinetics/PKG Health as a technology founder alongside Robert Griffiths. His University of Melbourne programme studies objective measurement of Parkinson’s and other movement disorders; that research produced the commercial Parkinson’s KinetiGraph. Founder attribution does not establish current executive employment after the Empatica acquisition.

Mandy Hagley is the Finance Director named in PKG Health’s February2025 leadership announcement and July2025 directory. The directory directly links her card to Samantha Hagley’s professional profile, while the issuer’s own social announcement uses Samantha; these primary links qualify the Mandy/Samantha name variant. Her role supports financial leadership during the company’s expansion. Continued employment after the2025 acquisition is not assumed.

Dan Bennett is PKG Health’s partnerships executive, promoted to Chief Business Officer in February2025. The issuer assigns him responsibility for life-science company and algorithm-licensing partnerships. Empatica’s own December2025 conference announcement still identifies him as PKG Health CBO after the acquisition. The individually published PKG portrait and linked danbennett1 profile distinguish this executive from the protected OurCrowd/Salus investor also named Dan Bennett.

Muhammad Umer is the engineering leader identified by PKG Health’s own November2023 directory as Vice President Technology and its July2025 directory as Chief Technology Officer. His company-linked professional profile identifies the Gen3 PKG Watch development project in2021–2023, involving hardware and firmware upgrades and Melbourne design partner Outerspace. His exact post-acquisition employment status is unpublished in the recovered issuer sources.

Neil Stevens led PKG Health’s Europe/Middle East business before promotion to Chief Commercial Officer EMEA in February2025. The company assigns this role responsibility for its clinical-care operations in Europe, the Middle East and Australia, after expanding patient access in those regions. His July2025 listing is the last recovered pre-acquisition directory; continued2026 tenure is not inferred.

Karen Krygier was PKG Health’s published Chief Strategy Officer in its November2023 directory. A company-sponsored TARGET-PD statistical analysis plan identifies her as Director of Clinical Research in September2020. Her work concerns clinical evidence for objective Parkinson’s monitoring. She is absent from the recovered July2025 operating directory, so continued employment or a precise departure date is not asserted.

Thomas Ulmer was appointed Global Kinetics CFO effective April2021 after serving as CFO of Immatics N.V. He initially advised the company from December2020. PKG Health appointed him interim CEO in February2025, following his Chief Operating and Financial Officer role; its July2025 directory labels him CEO. These are pre-acquisition appointments; no continuing independent CEO tenure after Empatica’s2025 acquisition is inferred.

Leighton Read is an American physician, entrepreneur and venture investor who joined Brandon Capital in2015. He previously led Interhealth Partners and Alloy Ventures, founded Affymax’s pharmaceutical division and was founding investor, chair and CEO of Aviron and Avidia. His primary biography identifies Rice University and University of Texas medical education plus Duke/Brigham internal-medicine training. He transitioned from Global Kinetics executive chair to non-executive chair in May2023 and is named PKG Health chairman in the completed2025 acquisition announcement.

Khalid Al-Saleh is Riyadh Valley Company’s chief executive officer as explicitly identified in itsSeptember25,2025 Abies Ventures FundII investment announcement and earlierMarch2021 Global Kinetics release. His own King Saud University faculty CV identifies Khalid Saad Al-Saleh as an associate professor of industrial engineering, with a1993 KingSaud bachelor’s degree and a2004 Birmingham PhD. His teaching and research cover human factors, ergonomics, cognitive and physical workload, patient safety, technology transfer and entrepreneurship. This is the university industrial engineer, distinct from the same-name clinical oncology/hematology physician. RVC’s full current executive directory and the continuation of his tenure after the latest dated confirmation are not independently published.

Abdulmajeed M. Al-Fadhli is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Audit Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Faisal S. Alyemni is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Nomination and Remuneration Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Sara A. Alhusaini is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Nomination and Remuneration Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Abeer Y. Alsalloom is the published chair of RVC’s audit committee. Her King Saud University faculty profile identifies Abeer Yousef Alsalloom as an accounting academic and head of the accounting department in the College of Business Administration. Her work examines gender, institutional constraints and professional practice in Saudi audit firms; the university profile lists internal auditing, corporate governance and management-accounting teaching. Exact RVC committee tenure dates are unpublished.

Abdulaziz A. Albassam is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Investment and Finance Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Abdulaziz M. Algabbani is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Investment and Finance Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Andrea Longhi is a currently published RVC board member. King Saud University’s own2025 transformation newsletters identify him as chief transformation officer overseeing the university’s transformation programme and its governance, people and institutional development. RVC’s website reuses the same portrait file for three differently named people, so no identity-unverified RVC image is attached. Exact RVC appointment date and further education history are unpublished.

Faiz A. Alahmary is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Board Member and Audit Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Abdullah A. Alsulaimi is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Board Member. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Ibrahim H. Al-Rashid is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Board Member and Nomination and Remuneration Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

Nasser A. Al Kadi is a named member of Riyadh Valley Company’s publicly listed governance structure, serving in Board Member and Investment and Finance Committee. RVC is King Saud University’s commercial knowledge-economy and strategic-project investment arm. The company’s current primary roster establishes this institutional affiliation; it does not publish a detailed individual career biography, education or appointment date. Committee and board affiliations are organizational governance roles, not evidence of a personal investment ticket.

David Fisher is partner emeritus at Brandon Capital. He helped found Brandon Capital after establishing Brandon Capital Management and its life-sciences pooled-development-fund activities. His earlier career includes Peptech leadership and Pharmacia work. His directory title Partner Emeritus expressly scopes his current affiliation. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Ibrahim S. Almojel is RVC’s currently published board chairman. Stanford’s own faculty biography identifies Ibrahim Almojel as a lecturer in management and founding partner of Khwarizmi Holding, with prior CEO roles at Saudi Industrial Development Fund and Saudi Aramco’s Wisayah investment arm. He studied electrical engineering and mathematics at Vanderbilt and earned electrical-engineering and management-science graduate degrees, including a PhD, at Stanford. RVC’s chair appointment date is unpublished.

Katharine Giles is venture partner - perth at Brandon Capital. She joined in2012 after investing at Stone Ridge Ventures. Her medical-device and startup work includes OncoRes leadership, digital breast-health tools and co-founding the Spark Co-Lab innovation-education initiative. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Yazeed A. Al-Humied is a currently published RVC board member. PIF’s own leadership biography identifies him as deputy governor and head of MENA investments, a role assumed in2021 after serving as chief of staff from his2015 arrival. He previously led the Capital Market Authority’s mergers-and-acquisitions team and worked at PwC. He holds an accounting degree from King Saud University. These institutional investment responsibilities do not establish a personal cash check.

Riyadh Valley Company (RVC) is the commercial knowledge-economy and strategic-project investment arm of King Saud University in Riyadh, Saudi Arabia. Its own institutional history records establishment in2010 by Royal Decree No.116 dated13/4/1431AH. It invests locally and internationally in growth-stage businesses to generate financial and strategic returns and connect university research and capabilities with commercial investment. The public royal-decree history establishes its university-company identity; an exact commercial-registration number and share-capital amount have not been independently verified. It is represented as a corporate Company investor, rather than an external private venture-fund manager. The venture portfolio spans biotechnology and healthcare, information and communications technology, sustainable resources, fintech, logistics and education. RVC also backs third-party venture funds, including deep-tech Abies Ventures FundII, and develops university-land projects for research, education, healthcare and other uses. Those investee funds are not RVC-managed fund closes. Its direct neuroscience relevance is the company’s own March25,2021 announcement of an investment in Australian Global Kinetics PtyLtd, developer of the Personal KinetiGraph objective Parkinson’s movement-monitoring system; ticket, stage and exact paying vehicle are unpublished. Corporate capital, university land, programme budgets and third-party fund targets are not asserted as new LP-fund cash raises. No RVC-managed closed LP vehicle has been verified. All seven currently published board members and nine published committee appointments are represented, with overlap retained as separate governance roles. CEO Khalid Al-Saleh is last explicitly confirmed by RVC in its September25,2025 investment release and by the university’s own industrial-engineering biography; continuing tenure beyond the last dated confirmation is qualified. This is the complete accessible named governance roster plus that source-confirmed executive, rather than a claimed census of private employees. Ten distinct authentic own-governance portraits and Khalid’s authentic university portrait are recorded. The website incorrectly repeats the same asset for Andrea Longhi, Faisal Alyemni and Sara Alhusaini; these three images are withheld pending identity-confirmed portraits. Exact director appointment dates and unpublished broader biographies remain unknown. The earlier May2025 chairman is not substituted for the current published chairman.

Roberto Solari is venture partner - united kingdom at Brandon Capital. His Brandon affiliation dates to2007. He co-founded Myricx Bio and previously led respiratory biology at GSK and the Medical Research Council’s commercialisation organisation, helping establish biotechnology spinouts. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Robert Daniels is venture partner - sydney at Brandon Capital. He joined in2021 following leadership of Elastagen from research spinout through clinical development and acquisition integration. His educational background spans Leeds science, UCL doctoral research and Swinburne entrepreneurship/innovation. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Robin Carr is advisor, united kingdom at Brandon Capital. He joined in2021 with drug-discovery leadership experience at Glaxo Wellcome, GSK and Astex. His earlier responsibilities encompassed small-molecule and biologics discovery platforms and partnered/internal therapeutic programmes. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Rana Ali is portfolio manager - new zealand at Brandon Capital. She joined in2021 following global animal-health innovation leadership at Argenta. Her experience covers pharmaceutical R&D/manufacturing, engineering projects, commercialisation, licensing and New Zealand/US operations. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Ian Holmes is preclinical project advisor - melbourne at Brandon Capital. He joined in2017 after medicinal-chemistry consulting, Cancer Therapeutics CRC leadership and research roles at GSK and Zeneca. He co-founded MycRx and Foray and advises therapeutic-development companies, bringing preclinical drug-discovery expertise. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Madeleine Pantaleo is office assistant at Brandon Capital. She joined in2025 with a healthcare background spanning enrolled nursing, patient-facing administration and specialist/allied-health settings. Her earlier Bupa work involved corporate relationships, payroll and finance administration. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Fiona Mascarenhas is financial accountant at Brandon Capital. She joined in2023 after finance roles at IKEA Dubai and Dixon Advisory Melbourne. Her professional membership is with Chartered Accountants Australia and New Zealand; she studied commerce at Monash and financial technologies at Swinburne. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Nikki Williams-Aslimoski is office manager & team assistant at Brandon Capital. She joined in2021 following international freight and logistics work at Expeditors and Clemenger. Her experience spans customs, transport coordination and distribution, before her office-management and team-support role. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Sean Creedon is senior fund accountant at Brandon Capital. He joined in2021 after fund-accounting experience at Citco, IFM and BNP Paribas. His background includes fund launches and accounting-system projects, with mathematics/economics and business-information-systems studies at University College Cork. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Deepali Dhawan is manager, corporate finance at Brandon Capital. She joined in2016 after fund-accounting work at Link Market Services and Primary Superannuation Services. Her finance responsibilities include reporting, audits, governance, systems and financial controls; earlier work involved telecommunications revenue analysis. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Robert Sicilia is head of investor relations at Brandon Capital. He joined in2024 after investment strategy, asset allocation and private-market work for Australian superannuation funds and JANA. His background includes manager diligence, co-investments, real assets and stakeholder relations. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Ruth Heenan is head of brand, marketing & communications at Brandon Capital. She joined in2025 with marketing and communications experience across healthcare, finance, nonprofit, government and commercial organisations. Her work emphasises public engagement, stakeholder relationships and strategic communications. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Dianne Climent-Ruiz is senior executive assistant & head of administration at Brandon Capital. She joined in2017 and supports the founding partners, investment team and portfolio executives. Her responsibilities include administration, stakeholder coordination and support for Brandon BioCatalyst’s governing directors; this is operational support rather than her own statutory board appointment. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Kate Groombridge is general counsel at Brandon Capital. She joined in2015 with litigation, commercial advisory and government-law experience. Her legal career includes Buddle Findlay and the UK Treasury Solicitor, with admissions in Victoria, England/Wales and New Zealand. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Dom Marot is chief financial officer at Brandon Capital. He joined in2024 with experience in UK and Australian investment finance. Previous responsibilities at Coller Capital and Rest Industry Super encompassed fund accounting, performance, investment operations and asset-owner finance. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Marium Rana is analyst, cureator at Brandon Capital. She entered CUREator in2025 after scientific work at Sygnature Discovery and commercial-strategy analysis at Kesmalea Therapeutics. Her Birmingham biochemistry doctorate and honours science degree concern anticancer discovery and translational research. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Aaron DeBono is program manager, cureator at Brandon Capital. He joined in2022 after biomedical business development at Murdoch Children’s Research Institute and medicinal-chemistry research at Monash. His translational work spans drug, device and digital-health commercialisation, including programmes involving GSK and defence research. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Patricia Rueda is program manager, cureator at Brandon Capital. She joined in2022 after corporate development at Audax/oNKo-innate and management of a Monash-Servier drug-discovery collaboration. Her experience spans translational project work, target assessment and lead optimisation. Current directory Program Manager supersedes older Analyst wording in her biography. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Christina Kulis is analyst, cureator at Brandon Capital. She joined in2021 and supports CUREator’s early biomedical commercialisation. Her earlier work includes Brandon investment analysis and Queensland drug-discovery programmes; a REDI industry fellowship supported her transition into venture work. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Amanda Vrselja is program head, cureator at Brandon Capital. She joined the founding CUREator team in2021 and leads its biomedical translation/incubation activities. Previously she was a clinical scientist at QUE Oncology, coordinating research strategy and a multinational PhaseII programme. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Melissa Byrne is senior investment associate at Brandon Capital. She joined in2018 after cardiovascular physiology and translational research at Baker Heart Institute. Her work includes preclinical device/therapeutic studies, early human trials and inventions supporting movement of medical research into clinical care. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Elliott Dunn is associate at Brandon Capital. He joined in2020 after research-project work at Blis Technologies and commercialisation analysis at Otago Innovation. His pharmacology background and2018 doctorate led to research-investment committee work and bioengineered burn-care projects. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Prashanth Rajan is associate at Brandon Capital. He joined in2021 and works from Sydney on NSW investment activity. His previous UniSA Ventures role covered commercialisation, licensing and intellectual-property portfolios, with operating experience at AbRegen. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Helga Mikkelsen is investment manager at Brandon Capital. She joined in2018 following work with Respirion’s founding team and respiratory/anti-infective technologies. Her training includes Danish chemical engineering/biotechnology, Cambridge microbiology and Imperial postdoctoral bacterial-genetics research. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Alex Delbridge is principal at Brandon Capital. He returned to Melbourne in2025 after Boston-based investing at Omega Funds, multiple-sclerosis research at Biogen and drug-pricing/access consulting at Putnam. His biography describes prior board-observer work across preclinical and clinical therapeutic programmes. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Michael Bettess is senior investment manager at Brandon Capital. His2016 Brandon appointment followed life-sciences business development at Monash and investment work at TTCF. He has worked on academic research commercialisation, pharmaceutical collaborations and biotechnology transactions, including Nexvet. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Duncan Mackintosh is senior investment manager at Brandon Capital. He joined in2016 to build New Zealand activities after technology-transfer leadership at Waikato’s commercialisation company. His career includes KiwiNet research-commercialisation collaboration and earlier veterinary practice, including UK foot-and-mouth-response responsibilities. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Trent Munro is venture partner at Brandon Capital. He joined in2026 after biotechnology research leadership at Queensland, executive work at Microba and Amgen. The public directory says Venture Partner while his individual biography says Partner; both published descriptions are retained without silently resolving the discrepancy. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Bob Soh is partner at Brandon Capital. His2016 move to Brandon followed medical and operational leadership at Nucleus Network, where he worked on early clinical studies and trial capabilities. He also helped establish Cardiora and guided its heart-failure programme through clinical development before licensing. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Chris Smith is partner at Brandon Capital. He entered Brandon in2012 after CSL business development and Cambridge postdoctoral research. His published portfolio-director affiliations concern Australian therapeutic businesses. He is distinct from the Chris Smith professionals at Playfair Capital, Curie Bio and Fractile. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Melissa McBurnie is partner & head of impact at Brandon Capital. Her prior work combines seed-stage investing at Terra Rossa, business development at Bio Innovation SA and postdoctoral research at Prince Henry’s Institute. Adelaide science/immunology training and a South Australia finance-focused MBA underpin her research-commercialisation and impact work. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Stephen Thompson is founding partner & managing director at Brandon Capital. His earlier career spans Apax Partners in London, product development at Cantab Pharmaceuticals and immunology research in London and California. His firm biography distinguishes current portfolio-director work from completed Elastagen and Longas affiliations. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Chris Nave is founding partner & managing director at Brandon Capital. He also leads Brandon BioCatalyst as CEO. Earlier roles included commercialisation leadership at Baker IDI, biotechnology management at Melbourne Ventures, Uniseed investing and pharmaceutical business development at Leiras. His research training at Melbourne encompasses an honours science degree and an endocrinology/physiology doctorate. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Abundry develops a decision intelligence and operating platform for energy systems. It combines digital twins, AI, optimization and energy-system data to help utilities, cities, industrial operators and infrastructure investors assess capacity, resilience and investment choices. Its software simulates alternative energy scenarios before construction, optimizes existing assets and loads in real time, and integrates decentralized assets into one operating system. Abundry also helps size battery and renewable infrastructure, plan grid connections and structure projects for third-party financing; this customer-project financing is distinct from capital raised by Abundry itself. The platform targets applications including data centers, cities, wind and solar installations and industrial sites. It launched publicly at Ygne on Gotland in June2026; public product descriptions do not establish independent performance validation or disclosed deployment scale.

Chuck Carignan is named on Anaconda Biomed’s current public board of directors. The issuer identifies the affiliation as Board Chairman. This confirms the board relationship without establishing a personal investment.

Christophe Cognard is named on Anaconda Biomed’s current public scientific advisory board. The issuer describes the clinician’s external clinical affiliation as Chairman of the department of Diagnostic and Therapeutic Neuroradiology, University Hospitals Purpan and Rangueil Toulouse, France Since Dec. 2002. This is an advisory relationship rather than company employment.

Tommy Andersson is named on Anaconda Biomed’s current public scientific advisory board. The issuer describes the clinician’s external clinical affiliation as Director for Education in Neuroendovascular Treatment, Karolinska University Hospital Shared director for the Section of Neurointervention and Angiography at KERIC. This is an advisory relationship rather than company employment.

Tina oversees global clinical trial execution, including CRO management. She earned a Bachelor’s Degree in Nursing from St. John Fisher University and a Master’s Degree in Public and Health Care Administration from SUNY (Brockport). She is currently working toward a PhD in Clinical Research from the University of Jamestown. Her career started in patient care, then she transitioned to field sales and market development before moving into corporate roles including field clinical engineering, clinical trial management, and clinical affairs at Boston Scientific, Recor, and Elixir Medical prior to joining Anaconda.

Monica is an accomplished leader with 25 years in the pharmaceutical and medical device spaces. For Anaconda she manages compliance with global regulatory and quality standards. She holds a BS in Chemistry & Biochemistry from UC, San Diego and a Masters in Biotechnology from San Jose State University. She is experienced in developing, clearing, and bringing novel technologies to market, including Stryker Endoscopy’s first wireless surgical monitor, Abbott’s AbsorbTM Stent, and Eargo’s first self-fitting OTC hearing aid.

With a degree in Chemical Sciences from Institut Químic de Sarrià, Barcelona and a PhD in Organic Chemistry, Barcelona, Dr. Arad has 15 years of experience in the biomedical field. After a period developing pharmaceutical compounds and photosensitizers for Cancer Photodynamic Therapy, he developed multiple materials for the medical devices industry: biopolymers and their formulations for controlled drug release applications, lubricious coatings and radiopaque materials for endovascular catheters, chemical enhancement of biomaterials for aortic percutaneous valves and advanced adhesives for medical applications.

Jordi has more than 30 years of experience, primarily as Industrial Director in Medical Device business. He has led Production, Maintenance, Quality Control, Supply Chain, Engineering and R&D in multinational and big family companies. He has expertise in process automation and process outsourcing in India, China, and Tunisia and has successfully implemented several Lean Manufacturing, 5S, TPM, and continuous improvement (Kaizen) processes. He has a telecommunications engineer degree from La Salle (Ramon Llull University), a Master’s degree in Total Quality Management from Polytechnical Catalonia University, and an Executive MBA degree from La Salle (Ramon Llull University) and St. Mary’s College (San Francisco, California).

Maria Jose began her career at Anaconda as the Administrative Officer, and her role has expanded over time to encompass budgeting, forecasting, and financial reporting. She earned her bachelor’s degree in Finance from Tecnologico de Monterrey, followed by a Master’s from ESNECA Business School with a focus on payroll, social insurance, settlements and contracts.

Inaki’s background includes a chemistry degree, a Master’s Degree in Organic Chemistry and Biochemistry, and a PhD in Drug Discovery (Organic Chemistry) at Institut Químic de Sarrià (Barcelona). He has successfully worked in drug discovery, biopolymers, and medical devices development both in research and management roles. His main fields of working include cancer, immunological and neurodegenerative disorders, and cardiovascular diseases. He has been involved from early stages of product conception to late regulatory and commercialization. His recent achievements have been in the field of cardiovascular medical devices, mainly drug eluting stents.

Hendrik has a master’s degree in Electronic Engineering and PhD in Biomedical Engineering from the University of Ghent, Belgium. He has over 25 years of experience in the development of innovative medical device technologies in early start-ups and in large size international companies. He has experience in the field of cardiac, vascular and neurological therapies, always with the aim of creating new standards of care. Prior to joining Anaconda Biomed, he was the co-founder and Vice-President of Clinical & Regulatory Affairs at ONWARD Medical in Lausanne, Switzerland, and previously was Vice-President of Clinical & Regulatory Affairs at Endosense, which was acquired by St Jude Medical (now Abbott.

Trent is a seasoned MedTech executive with over 25 years of leadership experience spanning early-stage clinical development to global commercial execution in venture-backed, market-disruptive medical technologies. He brings a strong combination of strategic vision, operational execution, and proven success in fundraising, market expansion, clinical strategy, and medical device innovation to his role at Anaconda. Previously he was CEO of Mercator MedSystems, and Global Vice President of Commercial Operations at IDEV Technologies (acquired by Abbott for $310M). He also held executive roles at ROX Medical, Omnisonics, and RITA Medical. Trent holds a Bachelor of Science in Business from Colorado State University and an MBA from the Paul Merage School of Business at the University of California, Irvine.

Anaconda Biomed S.L. is a Barcelona-area medical-device company developing funnel-based endovascular access and protection technology for neurovascular interventions, including mechanical thrombectomy in acute ischemic stroke caused by large-vessel occlusion. Co-founded in2015 by neurologist Marc Ribó and biomedical materials scientist Ofir Arad, it is registered in Spain under tax numberB66513474 and manufactures in Sant Quirze del Vallès. Its platform combines a self-expanding nitinol funnel, aspiration and temporary vascular-flow restriction, with devices intended to support clot retrieval and reduce downstream embolization. Clinical outcomes remain subject to the relevant product studies and indications. The issuer identifies ANA5 as CE-mark approved and the ANA Funnel Catheter as investigational-only in the United States. Its ongoing ATHENA pivotal IDE study is a prospective randomized327-subject trial. Trent Reutiman leads the company asCEO, alongside a published eight-person management team, external clinical scientific advisers and board representatives from its specialist healthcare investors. A closedUSD56M financing announced September23,2026 supports clinical development, manufacturing and regulatory work; the record separately identifies prior equity financings, investment commitments, public grant support and its signed EIB venture-debt facility.

ZAP Surgical Systems, Inc. develops robotic stereotactic radiosurgery equipment and treatment-planning software for brain and head-and-neck applications. Founded in 2014 by neurosurgeon and CyberKnife inventor John R. Adler, Jr., the company is headquartered in San Carlos, California. Its ZAP-X Gyroscopic Radiosurgery platform uses a linear accelerator and self-shielding design intended to avoid cobalt sources and a conventional shielded treatment vault. Software and robotic engineering underpin its treatment-delivery and planning platform. Published clearance and performance statements are issuer claims; investigational radiomodulation applications do not establish approved psychiatric indications or clinical efficacy. A September2026 listed-investor filing identifies the related Cayman holding company Zap Medical System, Ltd., led by the same founder, while the public operating brand identifies ZAP Surgical Systems, Inc.; these legal entities are qualified without merging unrelated records. The company announced completed USD81M equity financing in January2020 and USD78M Series E financing in November2024. A later USD11M warrant-exercise proposal is not recorded as completed cash. The genuine logo is the historical rendition published by its verified institutional investor GT Healthcare; eleven current executive portraits remain unavailable.

Alex Maslowski, PhD, leads software at ZAP Surgical. His biography describes over twenty years of medical and scientific software development, including computational physics, distributed computing and radiation models. He earned nuclear-engineering bachelor’s and doctoral degrees at Texas A&M. He worked on Transpire’s Acuros radiation-dosimetry software before Varian’s 2014 acquisition and subsequently led algorithm, machine-learning and cloud development related to Eclipse. His expertise supports the company’s treatment-planning and software platform.

Chris Pegano leads sales in the Americas at ZAP Surgical. His company biography describes more than twenty years of commercial experience in medical devices, neuroscience and brain oncology. His recent career includes MRI-guided laser interstitial thermal therapy, responsive neurostimulation and neuroendoscopy technologies. He previously served as a United States Army infantry officer and holds a bachelor’s degree from Rutgers University. The source does not establish a degree subject or additional current corporate appointments.

Derek T. DeScioli joined ZAP Surgical as chief operating officer in 2021. His published biography describes more than twenty years in medical technology and business growth, including leading IntraOp Medical through restructuring and commercial development in radiation oncology. Earlier experience includes 3M, Soliant Energy, Alpha Technologies and Astrodyne TDI. He holds a graduate degree from MIT and an engineering bachelor’s degree from Rutgers. His photograph is an unmodified company-published image naming him at a ZAP-X installation, rather than a generated headshot.

Hakan Baraner leads ZAP Surgical sales across EMEA, Central Asia, Malaysia and Indonesia. His published biography describes more than thirty years in international medical-device and capital-equipment sales. Previous positions include vice president of EMEA sales at ViewRay and commercial responsibilities for Accuray’s CyberKnife and TomoTherapy platforms, as well as ultrasound businesses Aloka and Vingmed Sound. He holds an undergraduate degree from the University of Maryland’s European programme in information-systems management and business studies.

Hemmings Wu, MD, PhD, joined ZAP Surgical as chief medical officer in 2025. His company biography describes a background in neurosurgery, neuroscience and medical technology, including neuromodulation and brain-computer-interface research. He previously worked as a neurosurgeon and research professor at Zhejiang University. He earned his medical degree at Peking University, completed clinical training at Shanghai Jiao Tong University, obtained a doctorate at KU Leuven and undertook postdoctoral research at Stanford. Clinical and device-development objectives remain source-attributed claims.

Jinhua Yang has been president of ZAP Surgical China since 2023. The published regional biography describes more than forty years of senior leadership and work on Chinese regulatory and market expansion, including the Beijing office, NMPA processes and local commercial infrastructure. His education includes a bachelor’s degree from Renmin University and a graduate fine-arts degree from UCLA. The regional leadership role is qualified within ZAP’s published group roster and does not establish an additional legal subsidiary or an independent investment vehicle.

John R. Adler, Jr., MD, founded ZAP Surgical in 2014 and is its chief executive. He invented the CyberKnife radiosurgery system and founded Accuray, and Stanford Medicine lists him as Professor Emeritus of Neurosurgery. His company biography describes Harvard undergraduate and medical training, Harvard neurosurgery training and a Karolinska fellowship with Lars Leksell. He also founded the Cureus medical publishing platform. The listed shareholder filing identifies him as John Rodenbeck Adler Jr.; he is distinct from similarly named politicians and his son Trip Adler. ZAP’s investigational radiomodulation programmes are separate from established device indications.

Mark Arnold joined ZAP Surgical in 2018 and leads marketing. His biography describes approximately twenty-five years in radiosurgery and radiation-oncology marketing, including serving as Elekta’s global vice president of marketing and holding marketing and product-management responsibilities at Accuray. He earned an MBA from the University of San Diego, with exchange coursework at Oxford’s Magdalen College, and an undergraduate business degree from the University of Nevada, Las Vegas. His published role concerns the medical-device company, not unrelated people with the same surname.

Nikita Kulkarni joined ZAP Surgical as chief financial officer in 2025. Her published biography describes nearly two decades in investment banking, corporate development, investor relations and pharmaceutical research. She previously led corporate development at Halozyme, co-led West Coast healthcare investment banking at Credit Suisse and held corporate-development and investor-relations responsibilities at Varian. Earlier work includes Morgan Stanley, Regeneron and Shire. She holds an MBA from Duke, a biotechnology master’s degree from Northeastern and a pharmacy bachelor’s degree from Mumbai University.

Robert Starr, also called Bob Starr in ZAP Surgical’s published biography, leads human resources. He has more than twenty-five years of HR and business experience across medical imaging, radiotherapy, sleep medicine and dental technology. Previous roles include vice president of human resources and administration at MicroDental and ProSomnus, and vice-president responsibilities at ADAC. He earned a social-sciences bachelor’s degree with a human-resources minor from California Polytechnic State University, San Luis Obispo. Both Robert and Bob identify this same published executive.

Robert Wiggers leads hardware engineering at ZAP Surgical. His biography describes more than thirty years in hardware and automation, including about seventeen years in medical technology. His background includes semiconductor wafer-handling robotics and engineering at Verb Surgical, Varian and RefleXion. He holds bachelor’s and master’s degrees in mechanical engineering and controls; the published source does not identify the institutions. His role concerns the company’s robotic radiosurgery hardware, not an inferred outside board appointment.

Santhosh Krishna Chandrabalan leads strategic growth at ZAP Surgical. The company describes responsibilities spanning growth strategy, new business development, software services and acquisitions. He previously held vice-president and general-manager responsibilities at Cornerstone Building Brands, and senior innovation and venture responsibilities at 3M and GE. His published education includes an MBA from Duke’s Fuqua School and advanced engineering and engineering-management degrees. These outside affiliations are career history, not additional current appointments or personal investment evidence.

Yair Bauer serves as president of ZAP Surgical Japan and vice president for Asia-Pacific. His published biography places him in Tokyo and describes over twenty-two years in neurosurgical technology, clinical development and commercial operations across the region. Before ZAP he held country-manager and Asia-Pacific leadership responsibilities at INSIGHTEC. These are qualified regional roles within the company’s public group leadership roster; no separate subsidiary legal identity or investment allocation is inferred.

Openseed VC backs experienced technology operators, domain experts and repeat founders as they start new companies, often before institutional venture funding. It offers initial angel investments of up to $150,000 and practical help with engineering, product development, recruiting, go-to-market work and fundraising readiness through an external operator network. Its investment themes cover business software and commerce, the future of work and health technology, including AI applications. The current website emphasizes Europe; its inaugural fund announcement described investing across Europe and Africa. Founder and general partner Maria Rotilu brings operating experience from Uber and Branch and earlier investing experience at Oxford Seed Fund and Octopus Ventures. The website identifies Openseed Ventures Ltd as the operating legal entity.

Product marketing professional featured in Openseed VC’s operator network with a published consumer fintech specialism. Monzo publishes her author page and writing about savings products.

Product marketing professional featured in Openseed VC’s operator network to support early company building. Mercury’s own author biography identifies her former work leading product marketing for new offerings including invoicing and taxes.

Founder and general partner of Openseed VC. She previously scaled products and teams at Uber and Branch, led Oxford Seed Fund while studying for an MBA at Oxford, and helped build and co-lead Octopus Ventures’ First Cheque Fund. The registry identifies her as Maria Oluwafunmike Rotilu, an active director of Openseed Ventures Ltd.

Product management professional featured in Openseed VC’s operator network. Oxford’s 2021 Seed Fund Founders Book names Nick Marcelli among that year’s fund team; this historical affiliation does not establish a current job.

Former statutory director of Openseed Ventures Ltd. The company registry records an appointment on July18,2023 and resignation on October4,2023. A venture-investing position or current affiliation with Openseed has not been established.

Guglielmo Foffani is publicly named by Newronika as Head of Neurophysiology and Neuromodulation - CIEN. The scientific advisory affiliation is separate from the outside academic title listed in the directory.

Aysegul Gunduz is publicly named by Newronika as Prof. Fixed Brain Mapping - University of Florida. The scientific advisory affiliation is separate from the outside academic title listed in the directory.

Sara Marceglia is publicly named by Newronika as Co-Founder, Associate Professor - University of Milan. The scientific advisory affiliation is separate from the outside academic title listed in the directory.

Jens Volkmann is publicly named by Newronika as Neurologist - University of Würzburg. The scientific advisory affiliation is separate from the outside academic title listed in the directory.

Alexandre Yip serves as Financial Controller at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to January 2020. Earlier professional experience described by the firm includes Deloitte.

Antonio Ruscitto serves as Client Servicing Principal - Investor Relations at Omnes Capital. The current directory assigns this position to Investor Relations. The published career history dates joining the firm or team to July 2025. The biography lists education or professional training at HEC. Earlier professional experience described by the firm includes Ardian.

Elena Moro is publicly named by Newronika as Neurologist - University of Grenoble. The scientific advisory affiliation is separate from the outside academic title listed in the directory.

Martin Thomas serves as Analyst at Omnes Capital. The current directory assigns this position to Portfolio Management. The published career history dates joining the firm or team to October 2025. The biography lists education or professional training at EM Lyon.

Moustapha Singare serves as Manager - Corporate Accounting at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to November 2021. Earlier corporate-accounting work includes RSM, BNP Cardif, TechnipFMC and Andera Partners.

Romain Ziouar-Cornec serves as Principal at Omnes Capital. The current directory assigns this position to Portfolio Management. The published career history dates joining the firm or team to April 2023. Earlier professional experience described by the firm includes PwC.

Syed Xeeshan Rizvi serves as Principal at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to July 2024. Prior utilities work at Vattenfall and Uniper included renewable-energy M&A across wind and solar; he holds a Mannheim MBA.

Alexandre Persyn serves as In-house Counsel at Omnes Capital. The current directory assigns this position to Legal Operations. The published career history dates joining the firm or team to 2008. Earlier professional experience described by the firm includes Crédit Agricole.

Chiayen Lin serves as ESG & Sustainability Manager at Omnes Capital. The current directory assigns this position to ESG & Sustainability. The published career history dates joining the firm or team to December 2023. The biography lists education or professional training at KEDGE. Earlier professional experience described by the firm includes Natixis.

Cristina Izquierdo Serrano serves as Associate at Omnes Capital. The current directory assigns this position to Digital Infrastructure. The published career history dates joining the firm or team to February 2024. Earlier professional experience described by the firm includes EY, KPMG.

Davide Pra serves as Associate at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to September 2024. The biography lists education or professional training at Bocconi.

Jacky Luu serves as Financial Controller at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to February 2021. Earlier professional experience described by the firm includes Deloitte.

Lysia Leclerc serves as Head of the Management Company Accounting at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to 2005. Previous employment includes Caisse des Dépôts subsidiaries; she holds a management and administration diploma.

Valérie Petrovic serves as Head of Funds Accounting and Treasury at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to 2007. Her career includes prior accounting work at Orange and Numéricâble and successive Omnes accounting and treasury promotions.

Wissal Lotfi serves as Risk and Compliance Analyst at Omnes Capital. The current directory assigns this position to Legal Operations. The published career history dates joining the firm or team to December 2023. The biography lists education or professional training at NEOMA.

Anaïs Petitjean serves as Analyst at Omnes Capital. The current directory assigns this position to Portfolio Management. The published career history dates joining the firm or team to March 2025. Earlier professional experience described by the firm includes Rothschild, Natixis.

Andres Lozano is publicly named by Newronika as Neurosurgeon - University of Toronto. The scientific advisory affiliation is separate from the outside academic title listed in the directory.

Arthur Mariaud serves as Principal at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The biography lists education or professional training at Imperial College. Previous energy-investment experience includes PEARL Infrastructure Capital and Aggreko, alongside Imperial College research and teaching.

Aymeric de Susbielle serves as Principal at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to September 2020. The biography lists education or professional training at ESSEC. Earlier professional experience described by the firm includes PwC.

Clément Henot serves as Analyst at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to February 2026. His analyst appointment followed an Omnes internship; earlier work includes M&A and investor relations, with emlyon business training.

Danielle Chucri serves as Executive Assistant to the CEO & Communications Coordinator at Omnes Capital. The current directory assigns this position to Communications, Executive Assistants. The published career history dates joining the firm or team to September 2024.

Hugo Hubert serves as Principal at Omnes Capital. The current directory assigns this position to Venture Capital & Growth. The published career history dates joining the firm or team to January 2020. His prior training covers data science at Télécom Paris and management and strategy at the London School of Economics.

Imane Essajradi serves as Fund Accounting Associate at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to February 2026. Earlier RSM private-equity work covered fund accounting and valuation; her graduate education spans ESC Pau and ENCG Agadir.

Karène Dubois serves as HR Officer at Omnes Capital. The current directory assigns this position to Human Resources. The published career history dates joining the firm or team to November 2017.

Marie-Emmanuelle Krantz serves as Paralegal at Omnes Capital. The current directory assigns this position to Legal Operations. The published career history dates joining the firm or team to September 2026. Earlier legal and administrative work includes eight years at Vivien & Associés; she studied languages and British literature.

Marwan Issac serves as Associate at Omnes Capital. The current directory assigns this position to Co-Investment. The published career history dates joining the firm or team to July 2024. The biography lists education or professional training at ESSEC. Earlier professional experience described by the firm includes PwC.

Mathis Fauvarque serves as Analyst - Investor Relations at Omnes Capital. The current directory assigns this position to Investor Relations. The published career history dates joining the firm or team to September 2025. Earlier professional experience described by the firm includes Rothschild.

Paul Maurens serves as Principal at Omnes Capital. The current directory assigns this position to Venture Capital & Growth. The published career history dates joining the firm or team to September 2022. Earlier professional experience described by the firm includes KPMG.

Quentin Mortreux serves as Analyst at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to March 2025. Earlier work includes renewable-energy industrial roles in London and Singapore and impact investing in Paris.

Soumaya Chouikh serves as Financial Controller at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to 2023.

Stéphanie Fehrenbach serves as Financial Controller at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to 2015. Earlier fund administration work includes CACEIS and private-equity subsidiaries in the LCL/Crédit Agricole group.

Wael Ilahi serves as IT Manager at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to January 2025. Earlier professional experience described by the firm includes Crédit Agricole, Société Générale.

Cassandra Bouet serves as Head of Compliance and Risk Management at Omnes Capital. The current directory assigns this position to Legal Operations. The published career history dates joining the firm or team to September 2017.

David Benayoun is an Accountant in Omnes Capital’s Finance Operations team. He joined the manager in February2020 after accounting work at the Sup de Pub and Sup de créa schools. His published professional education includes a BTS diploma in account management.

Fabienne Blondeau serves as Financial Controller at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to February 2022. The biography lists education or professional training at Sorbonne. Earlier professional experience described by the firm includes Crédit Agricole.